EP1173562A2 - Inhibition of histone deacetylase - Google Patents
Inhibition of histone deacetylaseInfo
- Publication number
- EP1173562A2 EP1173562A2 EP00954830A EP00954830A EP1173562A2 EP 1173562 A2 EP1173562 A2 EP 1173562A2 EP 00954830 A EP00954830 A EP 00954830A EP 00954830 A EP00954830 A EP 00954830A EP 1173562 A2 EP1173562 A2 EP 1173562A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- histone deacetylase
- hdac
- cell
- antisense
- ohgonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000003964 Histone deacetylase Human genes 0.000 title claims abstract description 338
- 108090000353 Histone deacetylase Proteins 0.000 title claims abstract description 338
- 230000005764 inhibitory process Effects 0.000 title abstract description 20
- 239000000074 antisense oligonucleotide Substances 0.000 claims abstract description 73
- 238000012230 antisense oligonucleotides Methods 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 72
- 230000014509 gene expression Effects 0.000 claims abstract description 55
- 230000006698 induction Effects 0.000 claims abstract description 43
- 230000004663 cell proliferation Effects 0.000 claims abstract description 37
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 36
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 210000004027 cell Anatomy 0.000 claims description 126
- 108091034117 Oligonucleotide Proteins 0.000 claims description 98
- 229940121649 protein inhibitor Drugs 0.000 claims description 95
- 239000012268 protein inhibitor Substances 0.000 claims description 95
- 230000000692 anti-sense effect Effects 0.000 claims description 71
- 230000002401 inhibitory effect Effects 0.000 claims description 32
- 150000007523 nucleic acids Chemical class 0.000 claims description 32
- 210000005170 neoplastic cell Anatomy 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 20
- 108020004414 DNA Proteins 0.000 claims description 15
- 102100021454 Histone deacetylase 4 Human genes 0.000 claims description 15
- 101000899259 Homo sapiens Histone deacetylase 4 Proteins 0.000 claims description 15
- 230000024245 cell differentiation Effects 0.000 claims description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 11
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 11
- 208000005623 Carcinogenesis Diseases 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 230000036952 cancer formation Effects 0.000 claims description 7
- 231100000504 carcinogenesis Toxicity 0.000 claims description 7
- 230000004069 differentiation Effects 0.000 claims description 7
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 7
- 108091028664 Ribonucleotide Proteins 0.000 claims description 6
- 230000017095 negative regulation of cell growth Effects 0.000 claims description 6
- 230000001613 neoplastic effect Effects 0.000 claims description 6
- 239000002336 ribonucleotide Substances 0.000 claims description 6
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 6
- 238000013518 transcription Methods 0.000 claims description 6
- 230000035897 transcription Effects 0.000 claims description 6
- 102000016397 Methyltransferase Human genes 0.000 claims description 5
- 108060004795 Methyltransferase Proteins 0.000 claims description 5
- 238000013519 translation Methods 0.000 claims description 5
- 125000005600 alkyl phosphonate group Chemical group 0.000 claims description 4
- -1 carboxymethylester Chemical compound 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims description 4
- 230000035407 negative regulation of cell proliferation Effects 0.000 claims description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- TTZMPOZCBFTTPR-UHFFFAOYSA-N O=P1OCO1 Chemical compound O=P1OCO1 TTZMPOZCBFTTPR-UHFFFAOYSA-N 0.000 claims description 3
- 102000055027 Protein Methyltransferases Human genes 0.000 claims description 3
- 108700040121 Protein Methyltransferases Proteins 0.000 claims description 3
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 150000003457 sulfones Chemical class 0.000 claims description 3
- 150000003568 thioethers Chemical class 0.000 claims description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract description 17
- 239000000203 mixture Substances 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 description 35
- 102000004169 proteins and genes Human genes 0.000 description 30
- 230000000694 effects Effects 0.000 description 25
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 18
- 108020004999 messenger RNA Proteins 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 238000001890 transfection Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 108010033040 Histones Proteins 0.000 description 9
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 9
- 230000009826 neoplastic cell growth Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000000636 Northern blotting Methods 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 7
- 230000036765 blood level Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 6
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 6
- 229960000237 vorinostat Drugs 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002342 ribonucleoside Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 description 3
- 230000010337 G2 phase Effects 0.000 description 3
- 229930189037 Trapoxin Natural products 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 125000001369 canonical nucleoside group Chemical group 0.000 description 3
- 230000006369 cell cycle progression Effects 0.000 description 3
- DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001378 electrochemiluminescence detection Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000004713 phosphodiesters Chemical class 0.000 description 3
- 150000008300 phosphoramidites Chemical class 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 108010060597 trapoxin A Proteins 0.000 description 3
- YECWTLGLNDDPGE-PIFXLSLCSA-N trichostatin C Chemical compound C(/[C@@H](C)C(=O)C=1C=CC(=CC=1)N(C)C)=C(/C)\C=C\C(=O)NO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YECWTLGLNDDPGE-PIFXLSLCSA-N 0.000 description 3
- YECWTLGLNDDPGE-UHFFFAOYSA-N trichostatin D Natural products C=1C=C(N(C)C)C=CC=1C(=O)C(C)C=C(C)C=CC(=O)NOC1OC(CO)C(O)C(O)C1O YECWTLGLNDDPGE-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000001531 bladder carcinoma Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000005289 controlled pore glass Substances 0.000 description 2
- 239000005549 deoxyribonucleoside Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- IDYKCXHJJGMAEV-RRKCRQDMSA-N 4-amino-5-fluoro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 IDYKCXHJJGMAEV-RRKCRQDMSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- LJIRBXZDQGQUOO-KVTDHHQDSA-N 6-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LJIRBXZDQGQUOO-KVTDHHQDSA-N 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 102100034523 Histone H4 Human genes 0.000 description 1
- 102100039999 Histone deacetylase 2 Human genes 0.000 description 1
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 208000034615 apoptosis-related disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 150000002972 pentoses Chemical group 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- WTWHYHPOGZUENL-KZKGWZQBSA-N trichostatin B Chemical compound O=C([C@H](C)/C=C(\C)/C=C/C(=O)NO[Fe](ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C=1C=CC(=CC=1)N(C)C)ONC(=O)\C=C\C(\C)=C\[C@@H](C)C(=O)C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 WTWHYHPOGZUENL-KZKGWZQBSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Definitions
- This invention relates to the inhibition of histone deacetylase expression and enzymatic activity.
- histone deacetylases Deacetylation of the core histones H1-H4 is mediated by a two related families of enzymes called the histone deacetylases.
- One family of histone deacetylases includes
- HDAC-1, HDAC-2, and HDAC-3 A second family of histone deacetylases includes HDAC- 4 (formerly HDAC-A), HDAC-5 (formerly HDAC-B), HDAC-C, HDAC-D, and HDAC-E.
- Histone deacetylase activity is thought to modulate the accessibility of transcription factors to enhancer and promoter elements. Indeed, an enrichment of underacetylated histone H4 has been found in transcriptionally silent regions of the genome (Taunton et al., Science 272: 408-411, 1996).
- Trichostatin A an antibiotic isolated from Streptomyces, has been shown to inhibit histone deacetylase activity and arrest cell cycle progression in cells in the Gl and G2 phases (Yoshida et aL, J. Biol. Chem. 265:
- the invention provides methods and reagents for inhibiting histone deacetylases at a nucleic acid level, as well as for inhibiting expression of a specific histone by inhibiting expression at the nucleic acid level.
- the invention allows the identification of and specific inhibition of a specific histone deacetylase involved in tumorigenesis.
- the invention provides an antisense oligonucleotide that inhibits the expression of a histone deacetylase.
- the histone deacetylase is HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E.
- the oligonucleotide inhibits more than one histone deacetylase, or the oligonucleotide inhibits all histone deacetylases.
- the oligonucleotide is a chimeric oligonucleotide or a hybrid ohgonucleotide.
- the oligonucleotide inhibits transcription of a nucleic acid molecule encoding the histone deacetylase.
- the nucleic acid molecule may be genomic DNA (e.g., a gene), cDNA, or RNA.
- the oligonucleotide inhibits translation of the histone deacetylase.
- the antisense oligonucleotide has at least one internucleotide linkage selected from the group consisting of phosphorothioate, phosphorodithioate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate and sulfone internucleotide linkages.
- the oligonucleotide comprises a ribonucleotide or 2'-O-substituted ribonucleotide region and a deoxyribonucleotide region.
- the invention provides a method for inhibiting a histone deacetylase in a cell comprising contacting the cell with the antisense oligonucleotide of the first aspect of the invention.
- cell proliferation is inhibited in the contacted cell.
- the cell is a neoplastic cell which may be in an animal, including a human, and which may be in a neoplastic growth.
- the method of the second aspect of the invention further comprises contacting the cell with a histone deacetylase protein inhibitor that interacts with and reduces the enzymatic activity of the histone deacetylase.
- the histone deacetylase protein inhibitor is operably associated with the antisense oligonucleotide.
- the invention provides a method for inhibiting neoplastic cell growth in an animal comprising administering to an animal having at least one neoplastic cell present in its body a therapeutically effective amount of the antisense ohgonucleotide of the first aspect of the invention with a pharmaceutically acceptable carrier for a therapeutically effective period of time.
- the method further comprises administering to the animal a therapeutically effective amount of a histone deacetylase protein inhibitor that interacts with and reduces the enzymatic activity of the histone deacetylase with a pharmaceutically acceptable carrier for a therapeutically effective period of time.
- a histone deacetylase protein inhibitor is operably associated with the antisense oligonucleotide.
- the invention provides a method for identifying a histone deacetylase that is involved in induction of cell proliferation comprising contacting a cell with an antisense oligonucleotide that inhibits the expression of a histone deacetylase, wherein inhibition of cell proliferation in the contacted cell identifies the histone deacetylase as a histone deacetylase that is involved in induction of cell proliferation.
- the cell is a neoplastic cell, and the induction of cell proliferation is tumorigenesis.
- the histone deacetylase is HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E.
- the invention provides a method for identifying a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell proliferation comprising contacting a histone deacetylase identified by the method of the fourth aspect of the invention with a candidate compound and measuring the enzymatic activity of the contacted histone deacetylase, wherein a reduction in the enzymatic activity of the contacted histone deacetylase identifies the candidate compound as a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell proliferation.
- the histone deacetylase protein inhibitor interacts with and reduces the enzymatic activity of fewer than all histone deacetylases.
- the invention provides a method for identifying a histone deacetylase that is involved in induction of cell differentiation comprising contacting a cell with an antisense ohgonucleotide that inhibits the expression of a histone deacetylase, wherein induction of differentiation in the contacted cell identifies the histone deacetylase as a histone deacetylase that is involved in induction of cell differentiation.
- the cell is a neoplastic cell.
- the histone deacetylase is HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E.
- the invention provides a method for identifying a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell differentiation comprising contacting a histone deacetylase identified by the method of the sixth aspect of the invention with a candidate compound and measuring the enzymatic activity of the contacted histone deacetylase, wherein a reduction in the enzymatic activity of the contacted histone deacetylase identifies the candidate compound as a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell differentiation.
- the histone deacetylase protein inhibitor interacts with and reduces the enzymatic activity of fewer than all histone deacetylases.
- the invention provides a histone deacetylase protein inhibitor identified by the method of the fifth or the seventh aspects of the invention.
- the histone deacetylase protein inhibitor is substantially pure.
- the invention provides a method for inhibiting cell proliferation in a cell comprising contacting a cell with at least two of the reagents selected from the group consisting of an antisense oligonucleotide that inhibits a histone deacetylase, a histone deacetylase protein inhibitor, an antisense ohgonucleotide that inhibits a DNA methyltransferase, and a DNA methyltransferase protein inhibitor.
- the inhibition of cell growth of the contacted cell is greater than the inhibition of cell growth of a cell contacted with only one of the reagents.
- each of the reagents selected from the group is substantiaUy pure.
- the cell is a neoplastic cell.
- the reagents selected from the group are operably associated. According to the invention, reagents found to specifically inhibit a histone deacetylase involved in neoplasia may be used as therapeutic agents to inhibit neoplastic cell growth in patients suffering from neoplasia.
- an antisense oligonucleotide that inhibits the expression of a histone deacetylase may be administered with a pharmaceutically-acceptable carrier (e.g., physiological sterile saline solution) via any route of administration to a patient suffering from neoplasia or hyperplasia in an attempt to alleviate any resulting disease symptom (e.g., death).
- a pharmaceutically-acceptable carrier e.g., physiological sterile saline solution
- an antisense oligonucleotide that inhibits the expression of a histone deacetylase may be incorporated into a gene therapy expression vector (e.g., a replication-deficient adenoviral vector), and phage particles carrying such vectors may be delivered with a pharmaceutically-acceptable carrier directly to the cells of the neoplastic or hyperplastic growth.
- a gene therapy expression vector e.g., a replication-deficient adenoviral vector
- phage particles carrying such vectors may be delivered with a pharmaceutically-acceptable carrier directly to the cells of the neoplastic or hyperplastic growth.
- Pharmaceutically-acceptable carriers and their formulations are well- known and generally described in, for example, Remington's Pharmaceutical Sciences (18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, PA, 1990).
- Figure 1 is a graphic representation of a Northern blotting analysis showing the dose- dependent abilities of representative, nonlimitmg, synthetic ohgonucleotides according to the invention that specifically bind to either HDAC-1-encoding nucleic acid or both HDAC-1- and HDAC-2-encoding nucleic acids to inhibit expression of HDAC-1 mRNA or both HDAC-1 mRNA and HDAC-2 mRNA, respectively.
- Figure 2 is a graphic representation of a Northern blotting analysis showing the dose- dependent abilities of representative, nonlimiting, synthetic oligonucleotides according to the invention that specifically bind to HDAC-2-encoding nucleic acid to inhibit expression of HDAC-2 mRNA.
- Figure 3 is a graphic representation of a Western blotting analysis showing the abilities of representative, nonlimiting, synthetic ohgonucleotides according to the invention that specifically bind to HDAC-2-encoding nucleic acid to specifically inhibit expression of HDAC-2 protein.
- Figure 4 is a graphic representation of a Western blotting analysis showing the abilities of representative, nonlimiting, synthetic ohgonucleotides according to the invention that specifically bind to either HDAC-1 -encoding nucleic acid or both HDAC-1- and HDAC- 2-encoding nucleic acid to inhibit expression of HDAC-1 protein or both HDAC-1 protein and HDAC-2 protein, respectively. Mismatched synthetic oligonucleotides were used as negative controls. Equal loading of all lanes is evidenced by the equivalent expression of actin.
- the invention provides methods and reagents for inhibiting a histone deacetylase at a nucleic acid level, as well as for inhibiting a specific histone deacetylase at the nucleic acid level.
- the reagents described herein that inhibit histone deacetylase at the nucleic acid level i.e., inhibiting transcription and translation
- therapeutical compositions for treating and/or alleviating the symptoms of neoplasia may be developed using the reagents of the invention that specifically inhibit a particular histone deacetylase involved in neoplasia.
- the reagents according to the invention are useful as analytical tools and as therapeutic tools, including as gene therapy tools.
- the invention also provides methods and compositions which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects.
- GenBank database sequences that are cited herein are hereby incorporated by reference to the same extent as if each was specifically and individually indicated to be inco ⁇ orated by reference.
- the invention provides an antisense ohgonucleotide that inhibits the expression of a histone deacetylase.
- the histone deacetylase is HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E.
- the ohgonucleotide inhibits more than one histone deacetylase, or the ohgonucleotide inhibits all histone deacetylases.
- the antisense ohgonucleotides according to the invention are complementary to a region of RNA or double-stranded DNA that encodes a histone deacetylase.
- the term "ohgonucleotide” includes polymers of two or more deoxyribonucleosides, ribonucleosides, or 2'-O-substituted ribonucleoside residues, or any combination thereof.
- such oligonucleotides have from about 8 to about 50 nucleoside residues, and most preferably from about 12 to about 30 nucleoside residues.
- the nucleoside residues may be coupled to each other by any of the numerous known intemucleoside linkages.
- Such intemucleoside linkages include without limitation phosphorothioate, phosphorodithioate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate, and sulfone internucleotide linkages.
- these intemucleoside linkages may be phosphodiester, phosphotriester, phosphorothioate, or phosphoramidate linkages, or combinations thereof.
- ohgonucleotide also encompasses such polymers having chemically modified bases or sugars and/or having additional substituents, including without limitation lipophilic groups, intercalating agents, diamines, and adamantane.
- the term "2'-O-substituted” means substitution of the 2' position of the pentose moiety with an -O-lower alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an -O-aryl or allyl group having 2-6 carbon atoms, wherein such alkyl, aryl, or allyl group may be unsubstituted or may be substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl, or amino groups; or such 2' substitution may be with a hydroxy group (to produce a ribonucleoside), an amino or
- the term "complementary" means having the abihty to hybridize to a genomic region, a gene, or an RNA transcript thereof under physiological conditions.
- Such hybridization is ordinarily the result of base-specific hydrogen bonding between complementary strands, preferably to form Watson-Crick or Hoogsteen base pairs, although other modes of hydrogen bonding, as well as base stacking can lead to hybridization.
- such hybridization can be inferred from the observation of specific gene expression inhibition, which may be at the level of transcription or translation (or both).
- antisense ohgonucleotides utilized in this aspect of the invention include chimeric ohgonucleotides and hybrid ohgonucleotides.
- a "chimeric ohgonucleotide” refers to an ohgonucleotide having more than one type of intemucleoside linkage.
- One preferred embodiment of such a chimeric ohgonucleotide is a chimeric ohgonucleotide comprising a phosphorothioate, phosphodiester or phosphorodithioate region, preferably comprising from about 2 to about 12 nucleotides, and an alkylphosphonate or alkylphosphonothioate region (see e.g., Pederson et al. U.S. Patent Nos. 5,635,377 and 5,366,878).
- such chimeric oligonucleotides contain at least three consecutive intemucleoside linkages selected from phosphodiester and phosphorothioate linkages, or combinations thereof.
- a "hybrid oligonucleotide” refers to an ohgonucleotide having more than one type of nucleoside.
- One preferred embodiment of such a hybrid oligonucleotide comprises a ribonucleotide or 2'-O-substituted ribonucleotide region, preferably comprising from about 2 to about 12 2'-O-substituted nucleotides, and a deoxyribonucleotide region.
- such a hybrid oligonucleotide will contain at least three consecutive deoxyribonucleosides and will also contain ribonucleosides, 2'-O- substituted ribonucleosides, or combinations thereof (see e.g., Metelev and Agrawal, U.S. Patent No. 5,652,355).
- nucleotide sequence and chemical structure of an antisense ohgonucleotide utilized in the invention can be varied, so long as the ohgonucleotide retains its ability to inhibit expression of a histone deacetylase. This is readily determined by testing whether the particular antisense oligonucleotide is active by quantitating the amount of mRNA encoding a histone deacetylase, quantitating the amount of histone deacetylase protein, quantitating the histone deacetylase enzymatic activity, or quantitating the abihty of histone deacetylase to inhibit cell growth in a an in vitro or in vivo cell growth assay, all of which are described in detail in this specification.
- Antisense oligonucleotides utilized in the invention may conveniently be synthesized on a suitable solid support using well-known chemical approaches, including H-phosphonate chemistry, phosphoramidite chemistry, or a combination of H-phosphonate chemistry and phosphoramidite chemistry (i.e., H-phosphonate chemistry for some cycles and phosphoramidite chemistry for other cycles).
- Suitable sohd supports include any of the standard solid supports used for solid phase ohgonucleotide synthesis, such as controlled- pore glass (CPG) (see, e.g., Pon, R. T., Methods in Molec. Biol. 20: 465-496, 1993).
- CPG controlled- pore glass
- Antisense oligonucleotides according to the invention are useful for a variety of purposes. For example, they can be used as "probes" of the physiological function of histone deacetylase by being used to inhibit the activity of histone deacetylase in an experimental cell culture or animal system and to evaluate the effect of inhibiting such histone deacetylase activity. This is accomplished by administering to a cell or an animal an antisense oligonucleotide that inhibits histone deacetylase expression according to the invention and observing any phenotypic effects.
- the antisense oligonucleotides according to the invention is preferable to traditional "gene knockout" approaches because it is easier to use, and can be used to inhibit histone deacetylase activity at selected stages of development or differentiation.
- the method according to the invention can serve as a probe to test the role of histone deacetylation in various stages of development.
- Preferred antisense ohgonucleotides of the invention inhibit either the transcription of a nucleic acid molecule encoding the histone deacetylase, or the translation of a nucleic acid molecule encoding the histone deacetylase.
- Histone deacetylase-encoding nucleic acids may be RNA or double stranded DNA regions and include, without limitation, intronic sequences, untranslated 5' and 3' regions, intron-exon boundaries as well as coding sequences from a histone deacetylase family member gene. For human sequences, see e.g., Yang et al., Proc. Natl. Acad. Sci.
- antisense oligonucleotides of the invention are complementary to regions of RNA or double- stranded DNA encoding a histone deacetylase (e.g., HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E).
- the antisense ohgnouncleotides according to the invention are complementary to regions of RNA or double-stranded DNA that encode HDAC-1, HDAC-2, HDAC-3, HDAC- 4, HDAC-5, HDAC-C, HDAC-D, and/or HDAC-E.
- the sequence of human HDAC-1 can be found in GenBank Accession No.
- U50079 (amino acid sequence in SEQ ID NO:24; nucleic acid sequence in SEQ ID NO:25.
- the sequence of human HDAC-2 can be found in GenBank Accession No. U31814 (amino acid sequence in SEQ ID NO: 26; nucleic acid sequence in SEQ ID NO: 27).
- the sequence of human HDAC-3 can be found in GenBank Accession No. U75697 (amino acid sequence in SEQ ID NO: 28; nucleic acid sequence in SEQ ID NO: 29).
- the sequence of human HDAC-4 (formerly human HDAC-A) in GenBank Accession No. AB006626 (amino acid sequence in SEQ ID NO: 30; nucleic acid sequence in SEQ ID NO: 31).
- human HDAC-5 (formerly human HDAC-B) can be found in GenBank Accession No. ABOl 1172 (amino acid sequence in SEQ ID NO: 32; nucleic acid sequence in SEQ ID NO: 33).
- the sequence of human HDAC-C can be found in GenBank Accession No. AC004994 (amino acid sequence in SEQ ID NO: 34; nucleic acid sequence in SEQ ID NO: 35).
- the sequence of human HDAC-D can be found in GenBank Accession No. AC004466 (nucleic acid sequence in SEQ ID NO: 36).
- the antisense oligonucleotides of the invention may also be complementary to regions of RNA or double-stranded DNA that encode histone deacetylases from non-human animals.
- preferred ohgonucleotides have nucleotide sequences of from about 13 to about 35 nucleotides which include the nucleotide sequences shown below as SEQ ID NOs: 1-18.
- ohgonucleotides have nucleotide sequences of from about 15 to about 26 nucleotides of the nucleotide sequences shown below.
- the ohgonucleotides shown below have phosphorothioate backbones, are 20-26 nucleotides in length, and are modified such that the terminal four nucleotides at the 5' end of the ohgonucleotide and the terminal four nucleotides at the 3' end of the ohgonucleotide each have 2' -O- methyl groups attached to their sugar residues.
- Antisense ohgonucleotide specific for human HDAC-1 (MG2608): 5'-GAA ACG TGA GGG ACT CAG CA-3' (SEQ ID NO: 1).
- Antisense ohgonucleotide specific for both human HDAC-1 and human HDAC-2 is a 25/25/25/25 mixture of four ohgonucleotides: 5'- CAG CAA ATT ATG GGT CAT GCG GAT TC-3' (SEQ ID NO: 2); 5'- CAG CAA GTT ATG AGT CAT GCG GAT TC-3' (SEQ ID NO: 3); 5'- CAG CAA ATT ATG AGT CAT GCG GAT TC-3' (SEQ ID NO: 4); and 5'- CAG CAA GTT ATG GGT CAT GCG GAT TC-3' (SEQ ID NO: 5).
- Antisense oligonucleotide specific for human HDAC-2 5'-TGC TGC TGC TGC TGC TGC TGC CG-3' (MG2628; SEQ ID NO: 6); 5'-CCT CCT GCT GCT GCT GCT GC-3' (MG2633; SEQ ID NO: 7); 5'-GGT TCC TTT GGT ATC TGT TT-3' (MG2635; SEQ ID NO: 8); and 5'-CTC CTT GAC TGT ACG CCA TG-3' (MG2636; SEQ ID NO: 9).
- the antisense oligonucleotides according to the invention may optionally be formulated with any of the well known pharmaceutically acceptable carriers or diluents (see preparation of pharmaceutically acceptable formulations in, e.g.. Remington's Pharmaceutical Sciences, 18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, PA, 1990).
- the invention provides a method for inhibiting a histone deacetylase in a cell comprising contacting the cell with the antisense ohgonucleotide that inhibits the expression of a histone deacetylase.
- cell prohferation is inhibited in the contacted cell.
- the antisense oligonucleotides according to the invention are useful in therapeutic approaches to human diseases including benign and malignant neoplasms by inhibiting cell prohferation in cells contacted with the antisense ohgonucleotides.
- inhibitorting cell prohferation is used to denote an ability of a histone deacetylase antisense ohgonucleotide or a histone deacetylase protein inhibitor (or combination thereof) to retard the growth of cells contacted with the ohgonucleotide or protein inhibitor, as compared to cells not contacted.
- Such an assessment of cell proliferation can be made by counting contacted and non-contacted cells using a Coulter Cell Counter (Coulter, Miami, FL) or a hemacyto meter.
- the term includes a retardation of cell prohferation that is at least 50% of non-contacted cells. More preferably, the term includes a retardation of cell prohferation that is 100% of non- contacted cells (i.e., the contacted cells do not increase in number or size). Most preferably, the term includes a reduction in the number or size of contacted cells, as compared to non- contacted cells.
- a histone deacetylase antisense oligonucleotide or a histone deacetylase protein inhibitor that inhibits cell proliferation in a contacted cell may induce the contacted cell to undergo growth retardation, to undergo growth arrest, to undergo programmed cell death (i.e., to apoptose), or to undergo necrotic cell death.
- the phrase "inducing cell prohferation” is used to denote the requirement of the presence or enzymatic activity of a histone deacetylase for cell proliferation in a normal (i.e., non-neoplastic) cell.
- a histone deacetylase that induces cell proliferation may or may not lead to increased cell proliferation; however, inhibition of a histone deacetylase that induces cell proliferation will lead to inhibition of cell proliferation.
- inducing cell differentiation is used to denote the ability of a histone deacetylase antisense oligonucleotide or histone deacetylase protein inhibitor (or combination thereof) to induce differentiation in a contacted cell as compared to a cell that is not contacted.
- a neoplastic cell when contacted with a histone deacetylase antisense ohgonucleotide or histone deacetylase protein inhibitor (or both) of the invention, may be induced to differentiate, resulting in the production of a daughter cell that is phylogenetically more advanced than the contacted cell.
- the cell prohferation inhibiting ability of the antisense ohgonucleotides according to the invention allows the synchronization of a population of a-synchronously growing cells.
- the antisense oligonucleotides of the invention may be used to arrest a population of non- neoplastic cells grown in vitro in the Gl or G2 phase of the cell cycle.
- Such synchronization allows, for example, the identification of gene and/or gene products expressed during the Gl or G2 phase of the cell cycle.
- Such a synchronization of cultured cells may also be useful for testing the efficacy of a new transfection protocol, where transfection efficiency varies and is dependent upon the particular cell cycle phase of the cell to be transfected.
- Use of the antisense ohgonucleotides of the invention allows the synchronization of a population of cells, thereby aiding detection of enhanced transfection efficiency.
- anti-neoplstic utility of the antisense ohgonucleotides according to the invention is described in detail elsewhere in this specification.
- the cell contacted with a histone deacetylase antisense ohgonucleotide is also contacted with a histone deacetylase protein inhibitor.
- histone deacetylase protein inhibitor denotes an active moiety capable of interacting with a histone deacetylase at the protein level and reducing the activity of that histone deacetylase.
- Histone deacetylase protein inhibitors include, without limitation, trichostatin A, trichostatin B, trichostatin C, depudecin, trapoxin, butyrate, suberoylanilide hydroxamic acid (SAHA), FR901228 (Fujisawa Pharmaceuticals), and acetyldinaline (el-Beltagi et al., Cancer Res. 53(13):3008-3014, 1993).
- a histone deacetylase protein inhibitor is a molecule that reduces the activity of a histone deacetylase to a greater extent than it reduces the activity of any unrelated protein. In a preferred embodiment, such reduction of the activity of a histone deacetylase is at least 5-fold, more preferably at least 10-fold, most preferably at least 50-fold. In another embodiment, the activity of a histone deacetylase is reduced 100-fold.
- a histone deacetylase protein inhibitor interacts with and reduces the activity of fewer than all histone deacetylases.
- all histone deacetylases is meant all of the members of both of the histone deacetylase families of proteins from a particular species of animal and includes, without limitation, HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E, all of which are considered “related proteins," as used herein.
- a preferred histone deacetylase protein inhibitor interacts with and inhibits HDAC- 1 and HDAC-2, but does not interact with and inhibit HDAC-3.
- a histone deacetylase protein inhibitor interacts with and reduces the activity of one histone deacetylase (e.g., HDAC-2), but does not interact with or reduce the activities of the other histone deacetylases (e.g., HDAC-1 and HDAC-3).
- a preferred histone deacetylase protein inhibitor is one that interacts with and reduces the enzymatic activity of a histone deacetylase that is involved in tumorigenesis.
- the histone deacetylase protein inhibitor is operably associated with the antisense oligonucleotide.
- the antisense oligonucleotides according to the invention may optionally be formulated well known pharmaceutically acceptable carriers or diluents.
- This formulation may further contain one or more one or more additional histone deacetylase antisense oligonucleotide(s), and/or one or more histone deacetylase protein inhibitor(s), or it may contain any other pharmacologically active agent.
- the antisense oligonucleotide is in operable association with a histone deacetylase protein inhibitor.
- operable association includes any association between the antisense ohgonucleotide and the histone deacetylase protein inhibitor which allows an antisense oligonucleotide to inhibit histone deacetylase-encoding nucleic acid expression and allows the histone deacetylase protein inhibitor to inhibit histone deacetylase enzymic activity.
- One or more antisense ohgonucleotide of the invention may be operably associated with one or more histone deacetylase protein inhibitor.
- the covalent linkage may be directly between the antisense oligonucleotide and the histone deacetylase protein inhibitor so as to integrate the histone deacetylase protein inhibitor into the backbone.
- the covalent linkage may be through an extended structure and may be formed by covalently linking the antisense ohgonucleotide to the histone deacetylase protein inhibitor through coupling of both the antisense oligonucleotide and the histone deacetylase protein inhibitor to a carrier molecule such as a carbohydrate, a peptide or a lipid or a glycohpid.
- Other preferred operable associations include lipophilic association, such as formation of a hposome containing an antisense ohgonucleotide and the histone deacetylase protein inhibitor covalently linked to a lipophilic molecule and thus associated with the liposome.
- hpophilic molecules include without hmitation phosphotidylcholine, cholesterol, phosphatidylethanolamine, and synthetic neoglycohpids, such as syalyllacNAc-HDPE.
- the operable association may not be a physical association, but simply a simultaneous existence in the body, for example, when the antisense ohgonucleotide is associated with one liposome and the protein effector is associated with another hposome.
- the invention provides a method for inhibiting neoplastic cell proliferation in an animal comprising administering to an animal having at least one neoplastic cell present in its body a therapeutically effective amount of the antisense oligonucleotide of the first aspect of the invention with a pharmaceutically acceptable carrier for a therapeutically effective period of time.
- the animal is a mammal, particularly a domesticated mammal. Most preferably, the animal is a human.
- the term "neoplastic cell" is used to denote a cell that shows aberrant cell growth.
- the aberrant cell growth of a neoplastic cell is increased cell growth.
- a neoplastic cell may be a hyperplastic cell, a cell that shows a lack of contact inhibition of growth in vitro, a benign tumor cell that is incapable of metastasis in vivo, or a cancer cell that is capable of metastases in vivo and that may recur after attempted removal.
- tumorgenesis is used to denote the induction of cell proliferation that leads to the development of a neoplastic growth.
- therapeutically effective amount and “therapeutically effective period of time” are used to denote known treatments at dosages and for periods of time effective to reduce neoplastic cell growth.
- such administration should be parenteral, oral, sublingual, transdermal, topical, intranasal, or intrarectal.
- the therapeutic composition is preferably administered at a sufficient dosage to attain a blood level of antisense oligonucleotide from about 0.1 ⁇ M to about 10 ⁇ M.
- concentrations typically be effective, and much higher concentrations may be tolerated.
- concentrations may vary considerably depending on the tissue, organ, or the particular animal or patient to be treated according to the invention.
- the therapeutic composition of the invention is administered systemically at a sufficient dosage to attain a blood level of antisense ohgonucleotide from about 0.01 ⁇ M to about 20 ⁇ M. In a particularly preferred embodiment, the therapeutic composition is administered at a sufficient dosage to attain a blood level of antisense ohgonucleotide from about 0.05 ⁇ M to about 15 ⁇ M. In a more preferred embodiment, the blood level of antisense ohgonucleotide is from about 0.1 ⁇ M to about 10 ⁇ M.
- a total dosage of antisense oligonucleotide will range from about 0.1 mg to about 200 mg ohgonucleotide per kg body weight per day. In a more preferred embodiment, a total dosage of antisense ohgonucleotide will range from about 1 mg to about 20 mg oligonucleotide per kg body weight per day. In a most preferred embodiment, a total dosage of antisense oligonucleotide will range from about 2 mg to about 10 mg ohgonucleotide per kg body weight per day. In a particularly preferred embodiment, the therapeutically effective amount of a histone deacetylase antisense oligonucleotide is about 0.5 mg ohgonucleotide per kg body weight per day.
- the method further comprises administering to the animal a therapeutically effective amount of a histone deacetylase protein inhibitor with a pharmaceutically acceptable carrier for a therapeutically effective period of time.
- a histone deacetylase protein inhibitor is operably associated with the antisense oligonucleotide. Methods for the operable association of a histone deacetylase protein inhibitor with a histone deacetylase antisense oligonucleotide are described above.
- the histone deacetylase protein inhibitor-containing therapeutic composition of the invention is administered systemically at a sufficient dosage to attain a blood level histone deacetylase protein inhibitor from about O.Ol ⁇ M to about lO ⁇ M.
- the therapeutic composition is administered at a sufficient dosage to attain a blood level of histone deacetylase protein inhibitor from about 0.05 ⁇ M to about lO ⁇ M.
- the blood level of histone deacetylase protein inhibitor is from about 0. l ⁇ M to about 7 ⁇ M.
- concentrations than this may be effective.
- a total dosage of histone deacetylase protein inhibitor will range from about 0.01 mg to about 5 mg protein effector per kg body weight per day.
- a total dosage of histone deacetylase protein inhibitor will range from about 0.1 mg to about 4 mg protein effector per kg body weight per day. In a most preferred embodiment, a total dosage of histone deacetylase protein inhibitor will range from about 0.1 mg to about 1 mg protein effector per kg body weight per day. In a particularly preferred embodiment, the therapeutically effective synergistic amount of histone deacetylase protein inhibitor (when administered with an antisense ohgonucleotide) is 0.1 mg per kg body weight per day.
- This aspect of the invention results in an improved inhibitory effect, thereby reducing the therapeutically effective concentrations of either or both of the nucleic acid level inhibitor (i.e., antisense oligonucleotide) and the protein level inhibitor (i.e., histone deacetylase protein inhibitor) required to obtain a given inhibitory effect as compared to those necessary when either is used individually.
- the therapeutically effective synergistic amount of either the antisense ohgonucleotide or the histone deacetylase inhibitor may be lowered or increased by fine tuning and altering the amount of the other component.
- the invention therefore provides a method to tailor the administration/treatment to the particular exigencies specific to a given animal species or particular patient.
- the invention provides a method for investigating the role of a particular histone deacetylase in cellular prohferation, including the proliferation of neoplastic cells.
- the cell type of interest is contacted with an amount of an antisense ohgonucleotide that inhibits the expression of a histone deacetylase, as described for the first aspect according to the invention, resulting in inhibition of expression of the histone deacetylase in the cell.
- the histone deacetylase is involved in the induction of cell prohferation.
- the histone deacetylase is HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E.
- histone deacetylase protein inhibitors may be generated that specifically inhibit the histone deacetylase involved in inducing cell proliferation, while not inhibiting other histone deacetylases not involved in inducing cell proliferation. Accordingly, in a fifth aspect, the invention provides a method for identifying a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in the induction of cell prohferation.
- This method comprises contacting a histone deacetylase identified as being involved in inducing cell proliferation with a candidate compound and measuring the enzymatic activity of the contacted histone deacetylase.
- a reduction in the enzymatic activity of the contacted histone deacetylase identifies the candidate compound as a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell prohferation.
- Measurement of the enzymatic activity of a histone deacetylase can be achieved using known methodologies. For example, Yoshida et al. (J. Biol. Chem.
- the histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell proliferation is a histone deacetylase protein inhibitor that interacts with and reduces the enzymatic activity of fewer than all histone deacetylases.
- the invention provides a method for identifying a histone deacetylase that is involved in induction of cell differentiation comprising contacting a cell with an antisense oligonucleotide that inhibits the expression of a histone deacetylase, wherein induction of differentiation in the contacted cell identifies the histone deacetylase as a histone deacetylase that is involved in induction of cell differentiation.
- the cell is a neoplastic cell.
- the histone deacetylase is HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E.
- the invention provides a method for identifying a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell differentiation comprising contacting a histone deacetylase identified by the method of the sixth aspect of the invention with a candidate compound and measuring the enzymatic activity of the contacted histone deacetylase, wherein a reduction in the enzymatic activity of the contacted histone deacetylase identifies the candidate compound as a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell differentiation.
- the histone deacetylase protein inhibitor interacts with and reduces the enzymatic activity of fewer than all histone deacetylases.
- the invention provides a histone deacetylase protein inhibitor identified by the method of the fifth or the seventh aspects of the invention.
- the histone deacetylase protein inhibitor is substantially pure.
- Substantially purified proteins can be achieve by any standard method including, without limitation, expression of recombinant protein, affinity chromatography, antibody- based affinity purification, and high performance hquid chromatography (HPLC; see, e.g., Fisher (1980) Laboratory Techniques in Biochemistry and Molecular Biology, Work and Burdon (eds.), Elsevier).
- a substantially purified protein is at least 80%, by weight, pure in that it is free from other proteins or naturally-occurring organic molecules. More preferably, a substantially purified protein is at least 90% pure, by weight. Most preferably, a substantially purified protein is at least 95% pure, by weight.
- the invention provides a method for inhibiting cell proliferation in a cell comprising contacting a cell with at least two of the reagents selected from the group consisting of an antisense ohgonucleotide that inhibits a histone deacetylase, a histone deacetylase protein inhibitor, an antisense ohgonucleotide that inhibits a DNA methyltransferase, and a DNA methyltransferase protein inhibitor.
- the inhibition of cell growth of the contacted cell is greater than the inhibition of cell growth of a cell contacted with only one of the reagents.
- each of the reagents selected from the group is substantially pure.
- the cell is a neoplastic cell.
- the reagents selected from the group are operably associated.
- DNA methyltransferase protein inhibitors include, without hmitation, 5-aza-2'- deoxycytidine (5-aza-dC), 5-fluoro-2'-deoxycytidine, 5-aza-cytidine (5-aza-C), or 5,6- dihydro-5-aza-cytidine.
- Example 1 Screening of Antisense Oligonucleotides To identify which antisense ohgonucleotides were most effective at inhibiting a specific histone deacetylase, a number of oligonucleotides were generated based on the sequences provided in GenBank Accession Number U50079 for HDAC-1 and GenBank Accession Number U31814 for HDAC-2.
- HDAC-1 and HDAC-2 are HDAC-1 and HDAC-2.
- T24 human bladder carcinoma cells (commercially available from the American Type Culture Collection (ATCC), Manassas, VA) were grown under suggested conditions. Before addition of ohgonucleotides, cells were washed with PBS (phosphate buffered saline). Next, hpofectin transfection reagent (Gibco-BRL Mississauga, Ontario), at a concentration of 6.25 ⁇ g/ml, was added to serum free OPTIMEM medium (GIBCO/BRL), which was then added to the cells.
- PBS phosphate buffered saline
- Ohgonucleotides to be screened were then added to different wells of cells (i.e., one oligonucleotide per well of cells). The same concentration of oligonucleotide (e.g., 50 nM) was used per well of cells. The cells were allowed to incubate with lipofectin and ohgonucleotide for 4 hours at 37 C in a cell culture incubator. The cells were then washed with PBS and returned to full serum-containing medium. Twenty- four hours later, the cells were harvested for determination of HD AC mRNA levels by Northern blotting analysis.
- oligonucleotide e.g., 50 nM
- RNA was prepared from cells by the guanidinium isothiocyanate standard procedure (see, e.g., Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, 1994), with the exception of an additional precipitation step in 2 M LiCl overnight at 4°C to purify RNA from cellular DNA contamination.
- Northern blotting analysis was performed according to standard protocols.
- Probes for HDAC-1 and HDAC-2 were full length cDNA clones generated by PCR amplification from the known sequences for each (e.g., GenBank Accession Nos. U50079 and U31814, respectively). These probes were radio labelled with
- the oligonucleotides which showed an ability to reduce the mRNA expression of a targeted histone deacetylase i.e., were able to inhibit transcription of the histone deacetylase mRNA
- T24 cells were transfected with ohgonucleotide using lipofectin as described above. Twenty-four hours later, the cells were lysed according to standard procedures.
- the whole cell extracts (50 ⁇ g) were resolved on 7-15% gradient SDS PAGE, transferred to PVDF membrane (Amersham, Arlington Heights, IL), and subjected to Western blotting analysis with rabbit polyclonal HDACl- and HDAC-2 specific antibodies (1:500, Santa Cmz Biotech., Santa Cruz, CA) were used. Detection was accomplished with a secondary anti- rabbit IgG-HR peroxidase antibody and an enhanced chemiluminescence detection kit (Amersham) accordingly to manufacturer's instructions. Based on our results, the following antisense ohgonucleotides were identified as being most effective at inhibiting the expression of targeted histone deacetylase as determined by both mRNA and protein expression blotting analysis.
- oliognucleotides are as follows: For inhibition of HDAC-1, Ohgonucleotide No. MG2608 having the sequence: 5'-GAA ACG TGA GGG ACT CAG CA-3' (SEQ ID NO: 10). For inhibition of both HDAC- 1 and HDAC-2, Oligonucleotide No. MG2610 is a
- Table I shows the antisense ohgonucleotides found to be most effective:
- HDAC-1 HDAC-1
- HDAC-1 / 2 HDAC-1 / 2
- HDAC- 1 MISMATCH CONTROL has the sequence: 5'-CAA UCG TCA GAG ACT CCG AA-3' (SEQ ID NO: 19).
- HDAC-1 / 2 MISMATCH CONTROL (MG2637), has a 225/25/25/25 mixture of four ohgonucleotides having the sequences:
- oligonucleotides having SEQ ID NOs: 10-23 were second generation oligonucleotides (i.e., 4x4 hybrids). That is, oligonucleotides having SEQ ID NOs: 10-23 were chemically modified as follows: A equals 2'-deoxyriboadenosine; C equals 2'- deoxyribocytidine; G equals 2'-deoxyriboguanosine; T equals 2'-deoxyribothymidine; A equals riboadenosine; U equals uridine; C equals ribocytidine; and G equals riboguanosine.
- underlined bases were 2'-methoxyribose substituted nucleotides.
- Non-underlined bases indicate deoxyribose nucleosides.
- the backbone of each oligonucleotide consisted of a phosphorothioate linkage between adjoining nucleotides.
- a number of oligonucleotides are next generated which are complementary to HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, and HDAC-E. These ohgonucleotides are based on the known nucleic acid sequences of these histone deacetylases (see, e.g., GenBank Accession No. U75697 for HDAC-3).
- Antisense oligonucleotides specific for one of these histone deacetylases are screened for efficacy at inhibiting expression of mRNA and protein as described above for HDAC-1, HDAC-1 / 2, and HDAC-2.
- antisense ohgonucleotides that inhibit more than one histone deacetylase e.g., HDAC-1 / 3 / C- specific
- HDAC-1 / 3 / C- specific are also generated by mixing antisense ohgonucleotides specific for each histone deacetylase and screened for efficacy.
- Oligonucleotides To determine the specificity and dose requirements of the antisense ohgonucleotides specific for histone deacetylase-encoding nucleic acid, the dose dependent inhibition of these ohgonucleotides on histone deacetylase mRNA expression was examined.
- T24 ceUs were transfected using lipofectin (as described in Example 1) using 10, 25, 50, or 100 nM oligonucleotide.
- the ceUs were harvested twenty-four hours foUowing transfection, RNA prepared, and Northern blotting analysis performed as described in Example 1 using radio labelled HDAC-1 and HDAC-2 cDNA as probe.
- Fig. 1 shows the dose dependent inhibition of HDAC-1 mRNA expression by both HDAC-1 and HDAC-1 / 2 antisense ohgonucleotides at 50-100 nM.
- HDAC-2 mRNA expression was inhibited by only the HDAC-1 / 2 antisense ohgonucleotide (MG2610) at 50-100 nM, while the HDAC-1 antisense oligonucleotide (MG2608) had no effect.
- the oligonucleotides used in the experiment, the results of which are shown in Fig. 1, were first generation oligonucleotides (i.e., were not chemically modified).
- the oligonucleotides used to obtain the results shown in Fig. 1 had sequences of SEQ ID NOs: 1- 5.
- Fig. 2 shows the dose-dependent inhibition of HDAC-2 mRNA by HDAC-2 antisense oligonucleotide.
- AU four HDAC-2 antisense oligonucleotide were able to reduce the level of HDAC-2 mRNA expression at 50-100 nM.
- MG2628 appeared particularly efficacious at reducing HDAC-2 mP T expression in this experiment.
- Second Generation Antisense Oligonucleotides To determine the ability of histone deacetylase antisense ohgonucleotides to inhibit protein expression, second generation versions of the HDAC-1, HDAC-1 / 2, and HDAC-2 antisense ohgonucleotides were generated. Each of these second generation antisense ohgonucleotides had a backbone consisting of a phosphorothioate linkage between each adjoining nucleotide. Moreover, the four terminal nucleotide residues at both the 5' and 3' ends of the olgonucleotide had sugar residues comprising a 2'-O-methyl group.
- This modification to the terminal nucleotide residues served to increase binding affinity of the ohgonucleotide to the targeted nucleic acid, and to increase the stability of the ohgonucleotide by inhibiting nuclease susceptibility.
- Fig. 3 shows the abUity of second generation HDAC-2 antisense ohgonucleotides to inhibit HDAC-2 protein expression.
- T24 ceUs were transfected with 0, 25, or 50 nM
- ceUs were transfected a second time with the same amount of the same oligonucleotide. Twenty- four hours after this (i.e., 48 hours after the first transfection), ceUular proteins were prepared, resolved on 7-15% gradient SDS-PAGE, and subjected to Western blotting analysis as described in Example 1 with rabbit polyclonal HDAC2 specific antibody (1:500, Santa Cruz Biotech).
- Fig. 3 shows the specific ability of the HDAC-1 / 2 and HDAC- , antisense ohgonucleotides to inhibit protein expression of both HDAC-1 and HDAC-2 or HDAC-1, respectively, when compared to the mismatch controls.
- T24 cells were transfected twice as described above with 50 nM oligonucleotide.
- Cell lysates were prepared twenty-four hours following the second transfection, resolved on 7-15% gradient SDS-PAGE, and transferred to PNDF membrane.
- the PVDF membrane blot was first blotted with anti-HDAC-1 antibody. FoUowing detection with horseradish peroxidase-labeUed secondary antibody and enhanced chemiluminescence, the blot was stripped, and re-probed with anti-HDAC-2 antibody. FoUowing detection, the blot was stripped for a second time and re-probed with an actin- specific antibody to verify equal protein loading in the lanes.
- HDAC-1 and HDAC-1 / 2 mismatch control oligonucleotides failed to inhibit HDAC-1 or HDAC-1 and HDAC-2 protein expression, respectively.
- HDAC-1 antisense ohgonucleotide effectively reduced expression of HDAC-1 protein
- HDAC-1 / 2 antisense oligonucleotide reduced protein expression of both HDAC- 1 and HDAC-2.
- Example 4 Identification of A Histone Deacetylase Involved in Induction of Cell Prohferation
- Antisense ohgonucleotides that inhibit expression of different histone deacetylases are screened to identify a histone deacetylase that induces cell prohferation in cultured ceUs.
- cultured normal human fibroblast ceUs are transfected with an antisense ohgonucleotide that inhibits the expression of a histone deacetylase.
- an antisense ohgonucleotide that inhibits the expression of a histone deacetylase. While any standard transfection protocol may be employed, including, without limitation, CaPO 4 precipitation, electroporation, DEAE-dextran), transfection using the lipofectin transfection reagent (Gibco- BRL) is preferred.
- An antisense oligonucleotide that inhibits the expression of a histone deacetylase that is found to inhibit cell proliferation when transfected into a normal cell identifies a histone deacetylase that is involved in induction of ceU prohferation in normal cells.
- T24 bladder carcinoma ceUs are transfected with histone deacetylase antisense oligonucleotides according to the invention and their growth pattern is observed and compared to that of untransfected control cells.
- T24 ceUs ATCC No. HTB-4
- T24 ceUs ATCC No. HTB-4
- cells are washed with phosphate buffered saline (PBS) and 5 ml of Opti-MEM media
- the cells are resuspended in PBS and counted on a Coulter Particle Counter to determine the total cell number.
- Mock-transfected T24 ceUs transfected with lipofectin and a control ohgonucleotide
- An antisense ohgonucleotide that inhibits the expression of a histone deacetylase that is found to inhibit ceU proliferation when transfected into a neoplastic cell identifies a histone deacetylase that is involved in induction of cell proliferation in neoplastic ceUs.
- a histone deacetylase antisense oligonucleotide of the invention is one that inhibits cell proliferation of neoplastic cells, but does not inhibit cell proliferation in normal cells.
- Example 5 A Histone Deacetylase Protein Inhibitor that Interacts With and Reduces the Enzymatic Activity of A Histone Deacetylase Involved in the Induction of Cell Proliferation
- a histone deacetylase that is identified as being involved in the induction of cell proliferation is used as a target for candidate compounds designed to interact with and inhibit its enzymatic activity.
- FR901228 available from Fujisawa Pharmaceuticals
- Candidate compounds can be derived from any source and may be naturally- occurring or synthetic, or may have naturaUy-occurring and synthetic components.
- Candidate compounds may also be designed to chemically resemble any of the known histone deacetylase protein inhibitors, including, without hmitation, trichostatin A, trichostatin C, trapoxin, depudecin, suberoylanilide hydro xamic acid (SAHA), FR901228, and butyrate.
- a pool of such compounds may be added to a histone deacetylase.
- a histone deacetylase is preferably one that is identified using the antisense ohgonucleotides of the invention as a histone deacetylase involved in induction of ceU prohferation.
- the histone deacetylase may be purified, for example, by using antibodies specific to that particular histone deacetylase (e.g., anti-HDAC-1 antibody commercially available from Santa Cruz Biotech.) or by recombinant production of the histone deacetylase in prokaryotic or eukaryotic cells.
- the histone deacetylase may also be present in a ceU which normally expresses the histone deacetylase.
- Pools of candidate compounds are added to the histone deacetylase, and the enzymatic activity of the histone deacetylase is measured.
- a pool of candidate compounds showing such a histone deacetylase inhibiting activity is sub-divided, and the subdivisions tested until one candidate compound is isolated having a histone deacetylase inhibiting activity. It will be understood that once a pool of candidate compounds is identified as having an ability to inhibit histone deacetylase enzymatic activity, the pool may be screened via various methods to ascertain the presence within the pool or one or more histone deacetylase protein inhibitor compounds.
- the pool may be subsequently screened on purified histone deacetylase.
- the candidate compound(s) found to be a histone & acetylase protein inhibitor inhibits the activity of fewer than aU histone deacetylases. More preferably, such a candidate compound inhibits only those histone deacetylases that are involved in the induction of cell proliferation. Even more preferably, the candidate compound that is identified as a histone deacetylase protein inhibitor is one that inhibits only one histone deacetylase, where that one histone deacetylase is involved in the induction of cell prohferation.
- the candidate compound that is identified as a histone deacetylase protein inhibitor is one that inhibits only one histone deacetylase, where that one histone deacetylase is involved in the induction of cell prohferation in neoplastic ceUs, but is not involved in the induction of cell prohferation in normal cells.
- a candidate compound that is a histone deacetylase protein inhibitor purified histone deacetylase is allowed to adhere to the bottom of wells in a 96-weU microtiter plate.
- Candidate compounds (or pools thereof) are then added to the plate, where each candidate compound has been modified with the covalent attachment of a detectable marker (e.g., a biotin label). Binding of the candidate compound to the plate- bound histone deacetylase is detected via addition of a secondary reagent that binds to the detectable marker (e.g., a streptavidin- labelled fluorophore), and subsequent analysis of the plate on a micro-titer plate reader.
- a secondary reagent that binds to the detectable marker
- Candidate compounds thus identified which interact with purified histone deacetylase are then screened for an abUity to inhibit the enzymatic activity of the histone deacetylase.
- Example 6 Anti-Neoplastic Effect of Histone Deacetylase Antisense Oligonucleotide on Tumor Cells in Vivo
- the purpose of this example is to illustrate the abihty of the histone deacetylase antisense ohgonucleotide of the invention to treat diseases responsive to histone deacetylase inhibition in animals, particularly mammals.
- This example further provides evidence of the ability of the methods and compositions of the invention to inhibit tumor growth in domesticated mammal.
- Eight to ten week old female BALB/c nude mice (Taconic Labs, Great Barrington, NY) are injected subcutaneously in the flank area with 2 x 10 6 preconditioned A549 human lung carcinoma cells.
- Preconditioning of these cells is done by a minimum of three consecutive tumor transplantations in the same strain of nude mice. Subsequently, tumor fragments of approximately 30 mgs are excised and implanted subcutaneously in mice, in the left flank area under Forene anesthesia (Abbott Labs., Geneva, Switzerland). When the tumors reaches a mean volume of 100 mm 3 , the mice are treated intravenously, by daily bolous infusion into the taU vein, with ohgonucleotide saline preparations containing 0.1-6 mg/kg of antisense oligonucleotide (Sigma, St. Louis, MO). The optimal final concentration of the oligonucleotide is established by dose response experiments according to standard protocols.
- Tumor volume is calculated according to standard methods every second day post infusion (e.g., Meyer et al., Int. J. Cancer 43:851- 856 (1989)).
- Treatment with the ohgonucleotides according to the invention causes a significant reduction in tumor weight and volume relative to controls treated with saline only (i.e., no ohgonucleotide) or controls treated with sahne plus a control, non-specific ohgonucleotide.
- the activity of histone deacetylase when measured is expected to be significantly reduced relative to saline treated controls.
- Example 7 Synergistic Anti-Neoplastic Effect of Histone Deacetylase Antisense Oligonucleotide and Histone Deacetylase Protein Inhibitor on Tumor Cells in Vivo
- the purpose of this example is to Ulustrate the abihty of the histone deacetylase antisense ohgonucleotide and the histone deacetylase protein inhibitor of the invention to inhibit tumor growth in a mammal.
- mice bearing implanted A549 tumors (mean volume 100 mm 3 ) are treated daUy with saline preparations containing from about 0.1 mg to about 30 mg per kg body weight of histone deacetylase antisense ohgonucleotide.
- mice A second group of mice is treated daily with pharmaceutically acceptable preparations containing from about 0.01 mg to about 5 rag per kg body weight of histone deacetylase protein inhibitor.
- Some mice receive both the antisense oligonucleotide and the histone deacetylase protein inhibitor.
- one group may receive the antisense oligonucleotide and the histone deacetylase protein inhibitor simultaneously intravenously via the tail vein.
- Another group may receive the antisense ohgonucleotide via the tail vein, and the histone deacetylase protein inhibitor subcutaneously.
- Yet another group may receive both the antisense oligonucleotide and the histone deacetylase protein inhibitor simultaneously via a subcutaneous injection.
- mice ⁇ e similarly estabhshed which receive no treatment e.g., saline only
- a mismatch antisense oligonucleotide only e.g., a control compound that does not inhibit histone deacetylase activity
- a control compound that does not inhibit histone deacetylase activity e.g., a control compound that does not inhibit histone deacetylase activity
- a control compound that does not inhibit histone deacetylase activity e.g., a control compound that does not inhibit histone deacetylase activity
- mismatch antisense ohgonucleotide with control compound e.g., a control compound that does not inhibit histone deacetylase activity
- Tumor volume is measured with calipers.
- Treatment with the antisense oligonucleotide plus the histone deacetylase protein inhibitor according to the invention causes a significant reduction in tumor weight and volume relative to controls.
- the antisense oligonucleotide and the histone deacetylase protein inhibitor inhibit the expression and activity of the same histone deacetylase.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention relates to the inhibition of histone deacetylase expression and enzymatic activity and, in particular, to the inhibition of a specific histone deacetylase. The invention also relates to compositions comprising antisense oligonucleotides and methods of using the same to inhibit a histone deacetylase. Also disclosed are methods for identifying a histone deacetylase involved in induction of cell proliferation, and methods for identifying compounds that interact with and reduce the enzymatic activity of such a histone deacetylase.
Description
INHIBITION OF HISTONE DEACETYLASE
RELATED APPLICATIONS This application claims priority from U.S. provisional application serial number
60/132,287, filed on May 3, 1999, which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Field of the Invention This invention relates to the inhibition of histone deacetylase expression and enzymatic activity.
Summary of the Related Art
Deacetylation of the core histones H1-H4 is mediated by a two related families of enzymes called the histone deacetylases. One family of histone deacetylases includes
HDAC-1, HDAC-2, and HDAC-3. A second family of histone deacetylases includes HDAC- 4 (formerly HDAC-A), HDAC-5 (formerly HDAC-B), HDAC-C, HDAC-D, and HDAC-E. Histone deacetylase activity is thought to modulate the accessibility of transcription factors to enhancer and promoter elements. Indeed, an enrichment of underacetylated histone H4 has been found in transcriptionally silent regions of the genome (Taunton et al., Science 272: 408-411, 1996).
Functional histone deacetylases have been implicated as a requirement in cell cycle progression in both normal and neoplastic cells. Trichostatin A (TCA), an antibiotic isolated from Streptomyces, has been shown to inhibit histone deacetylase activity and arrest cell cycle progression in cells in the Gl and G2 phases (Yoshida et aL, J. Biol. Chem. 265:
17174-17179, 1990; Yoshida et al., Exp. Cell Res. 177: 122-131, 1988). Other inhibitors of histone deacetylase activity, including trichostatin C, trapoxin, depudecin, suberoylanilide hydroxamic acid (SAHA), FR901228 (Fujisawa Pharmaceuticals), and butyrate, have been found to similarly inhibit cell cycle progression in cells (Taunton et aL, Science 272: 408- 411, 1996; Kijima et al., J. Biol. Chem. 268(30):22429-22435, 1993; Kwon et al., Proc. Natl. Acad. Sci. USA 95(7):3356-61, 1998).
The known inhibitors of histone deacetylase are all natural product and are all small molecules that inhibit histone deacetylase activity at the protein level. Moreover, all of the known histone deacetylase inhibitors are non-specific for a particular histone deacetylase enzyme, and more or less inhibit all members of both the histone deacetylase families equally.
Therefore, there remains a need to develop reagents for inhibiting histone deacetylases at a genetic level, as well as for inhibiting expression of a specific histone deacetylase. There is also a need for the development of methods for using these reagents to identify and inhibit a specific histone deacetylase involved in tumorigenesis.
BRIEF SUMMARY OF THE INVENTION
The invention provides methods and reagents for inhibiting histone deacetylases at a nucleic acid level, as well as for inhibiting expression of a specific histone by inhibiting expression at the nucleic acid level. The invention allows the identification of and specific inhibition of a specific histone deacetylase involved in tumorigenesis.
Accordingly, in a first aspect, the invention provides an antisense oligonucleotide that inhibits the expression of a histone deacetylase. In certain embodiments of this aspect of the invention, the histone deacetylase is HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E. In certain other embodiments, the oligonucleotide inhibits more than one histone deacetylase, or the oligonucleotide inhibits all histone deacetylases. Preferably, the oligonucleotide is a chimeric oligonucleotide or a hybrid ohgonucleotide.
In certain preferred embodiments of the first aspect of the invention, the oligonucleotide inhibits transcription of a nucleic acid molecule encoding the histone deacetylase. The nucleic acid molecule may be genomic DNA (e.g., a gene), cDNA, or RNA. In other embodiments, the oligonucleotide inhibits translation of the histone deacetylase.
In various embodiments of the first aspect of the invention, the antisense oligonucleotide has at least one internucleotide linkage selected from the group consisting of phosphorothioate, phosphorodithioate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate and sulfone internucleotide linkages. In certain embodiments, the oligonucleotide comprises a ribonucleotide or 2'-O-substituted ribonucleotide region and a deoxyribonucleotide region. In a second aspect, the invention provides a method for inhibiting a histone deacetylase in a cell comprising contacting the cell with the antisense oligonucleotide of the first aspect of the invention. In certain preferred embodiments of the second aspect of the invention, cell proliferation is inhibited in the contacted cell. In preferred embodiments, the cell is a neoplastic cell which may be in an animal, including a human, and which may be in a neoplastic growth. In certain preferred embodiments, the method of the second aspect of the invention further comprises contacting the cell with a histone deacetylase protein inhibitor
that interacts with and reduces the enzymatic activity of the histone deacetylase. Preferably, the histone deacetylase protein inhibitor is operably associated with the antisense oligonucleotide.
In a third aspect, the invention provides a method for inhibiting neoplastic cell growth in an animal comprising administering to an animal having at least one neoplastic cell present in its body a therapeutically effective amount of the antisense ohgonucleotide of the first aspect of the invention with a pharmaceutically acceptable carrier for a therapeutically effective period of time.
In certain preferred embodiments of the third aspect of the invention, the method further comprises administering to the animal a therapeutically effective amount of a histone deacetylase protein inhibitor that interacts with and reduces the enzymatic activity of the histone deacetylase with a pharmaceutically acceptable carrier for a therapeutically effective period of time. Preferably, the histone deacetylase protein inhibitor is operably associated with the antisense oligonucleotide. In a fourth aspect, the invention provides a method for identifying a histone deacetylase that is involved in induction of cell proliferation comprising contacting a cell with an antisense oligonucleotide that inhibits the expression of a histone deacetylase, wherein inhibition of cell proliferation in the contacted cell identifies the histone deacetylase as a histone deacetylase that is involved in induction of cell proliferation. In certain preferred embodiments, the cell is a neoplastic cell, and the induction of cell proliferation is tumorigenesis. In preferred embodiments, the histone deacetylase is HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E.
In a fifth aspect, the invention provides a method for identifying a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell proliferation comprising contacting a histone deacetylase identified by the method of the fourth aspect of the invention with a candidate compound and measuring the enzymatic activity of the contacted histone deacetylase, wherein a reduction in the enzymatic activity of the contacted histone deacetylase identifies the candidate compound as a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell proliferation. In certain preferred embodiments, the histone deacetylase protein inhibitor interacts with and reduces the enzymatic activity of fewer than all histone deacetylases.
In a sixth aspect, the invention provides a method for identifying a histone deacetylase that is involved in induction of cell differentiation comprising contacting a cell with an antisense ohgonucleotide that inhibits the expression of a histone deacetylase, wherein induction of differentiation in the contacted cell identifies the histone deacetylase as a histone deacetylase that is involved in induction of cell differentiation. In certain preferred embodiments, the cell is a neoplastic cell. In preferred embodiments, the histone deacetylase is HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E.
In a seventh aspect, the invention provides a method for identifying a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell differentiation comprising contacting a histone deacetylase identified by the method of the sixth aspect of the invention with a candidate compound and measuring the enzymatic activity of the contacted histone deacetylase, wherein a reduction in the enzymatic activity of the contacted histone deacetylase identifies the candidate compound as a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell differentiation. In certain preferred embodiments, the histone deacetylase protein inhibitor interacts with and reduces the enzymatic activity of fewer than all histone deacetylases.
In an eighth aspect, the invention provides a histone deacetylase protein inhibitor identified by the method of the fifth or the seventh aspects of the invention. Preferably, the histone deacetylase protein inhibitor is substantially pure. In a ninth aspect, the invention provides a method for inhibiting cell proliferation in a cell comprising contacting a cell with at least two of the reagents selected from the group consisting of an antisense oligonucleotide that inhibits a histone deacetylase, a histone deacetylase protein inhibitor, an antisense ohgonucleotide that inhibits a DNA methyltransferase, and a DNA methyltransferase protein inhibitor. In one embodiment, the inhibition of cell growth of the contacted cell is greater than the inhibition of cell growth of a cell contacted with only one of the reagents. In certain embodiments, each of the reagents selected from the group is substantiaUy pure. In preferred embodiments, the cell is a neoplastic cell. In yet additional preferred embodiments, the reagents selected from the group are operably associated. According to the invention, reagents found to specifically inhibit a histone deacetylase involved in neoplasia may be used as therapeutic agents to inhibit neoplastic cell growth in
patients suffering from neoplasia. For example, an antisense oligonucleotide that inhibits the expression of a histone deacetylase may be administered with a pharmaceutically-acceptable carrier (e.g., physiological sterile saline solution) via any route of administration to a patient suffering from neoplasia or hyperplasia in an attempt to alleviate any resulting disease symptom (e.g., death). Likewise, an antisense oligonucleotide that inhibits the expression of a histone deacetylase may be incorporated into a gene therapy expression vector (e.g., a replication-deficient adenoviral vector), and phage particles carrying such vectors may be delivered with a pharmaceutically-acceptable carrier directly to the cells of the neoplastic or hyperplastic growth. Pharmaceutically-acceptable carriers and their formulations are well- known and generally described in, for example, Remington's Pharmaceutical Sciences (18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, PA, 1990).
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a graphic representation of a Northern blotting analysis showing the dose- dependent abilities of representative, nonlimitmg, synthetic ohgonucleotides according to the invention that specifically bind to either HDAC-1-encoding nucleic acid or both HDAC-1- and HDAC-2-encoding nucleic acids to inhibit expression of HDAC-1 mRNA or both HDAC-1 mRNA and HDAC-2 mRNA, respectively.
Figure 2 is a graphic representation of a Northern blotting analysis showing the dose- dependent abilities of representative, nonlimiting, synthetic oligonucleotides according to the invention that specifically bind to HDAC-2-encoding nucleic acid to inhibit expression of HDAC-2 mRNA.
Figure 3 is a graphic representation of a Western blotting analysis showing the abilities of representative, nonlimiting, synthetic ohgonucleotides according to the invention that specifically bind to HDAC-2-encoding nucleic acid to specifically inhibit expression of HDAC-2 protein. Figure 4 is a graphic representation of a Western blotting analysis showing the abilities of representative, nonlimiting, synthetic ohgonucleotides according to the invention that specifically bind to either HDAC-1 -encoding nucleic acid or both HDAC-1- and HDAC- 2-encoding nucleic acid to inhibit expression of HDAC-1 protein or both HDAC-1 protein and HDAC-2 protein, respectively. Mismatched synthetic oligonucleotides were used as negative controls. Equal loading of all lanes is evidenced by the equivalent expression of actin.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The invention provides methods and reagents for inhibiting a histone deacetylase at a nucleic acid level, as well as for inhibiting a specific histone deacetylase at the nucleic acid level. The reagents described herein that inhibit histone deacetylase at the nucleic acid level (i.e., inhibiting transcription and translation) allows the identification of a specific histone deacetylase which is involved in neoplasia. Moreover, therapeutical compositions for treating and/or alleviating the symptoms of neoplasia may be developed using the reagents of the invention that specifically inhibit a particular histone deacetylase involved in neoplasia. The reagents according to the invention are useful as analytical tools and as therapeutic tools, including as gene therapy tools. The invention also provides methods and compositions which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects. The patent and scientific literature referred to herein establishes knowledge that is available to those with skill in the art. The issued patents, apphcations, and references, including GenBank database sequences, that are cited herein are hereby incorporated by reference to the same extent as if each was specifically and individually indicated to be incoφorated by reference.
In a first aspect, the invention provides an antisense ohgonucleotide that inhibits the expression of a histone deacetylase. In certain embodiments of this aspect of the invention, the histone deacetylase is HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E. In certain embodiments, the ohgonucleotide inhibits more than one histone deacetylase, or the ohgonucleotide inhibits all histone deacetylases.
The antisense ohgonucleotides according to the invention are complementary to a region of RNA or double-stranded DNA that encodes a histone deacetylase. For purposes of the invention, the term "ohgonucleotide" includes polymers of two or more deoxyribonucleosides, ribonucleosides, or 2'-O-substituted ribonucleoside residues, or any combination thereof. Preferably, such oligonucleotides have from about 8 to about 50 nucleoside residues, and most preferably from about 12 to about 30 nucleoside residues. The nucleoside residues may be coupled to each other by any of the numerous known intemucleoside linkages. Such intemucleoside linkages include without limitation phosphorothioate, phosphorodithioate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate,
carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate, and sulfone internucleotide linkages. In certain preferred embodiments, these intemucleoside linkages may be phosphodiester, phosphotriester, phosphorothioate, or phosphoramidate linkages, or combinations thereof. The term ohgonucleotide also encompasses such polymers having chemically modified bases or sugars and/or having additional substituents, including without limitation lipophilic groups, intercalating agents, diamines, and adamantane. For purposes of the invention the term "2'-O-substituted" means substitution of the 2' position of the pentose moiety with an -O-lower alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an -O-aryl or allyl group having 2-6 carbon atoms, wherein such alkyl, aryl, or allyl group may be unsubstituted or may be substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl, or amino groups; or such 2' substitution may be with a hydroxy group (to produce a ribonucleoside), an amino or a halo group, but not with a 2'-H group.
For purposes of the invention, the term "complementary" means having the abihty to hybridize to a genomic region, a gene, or an RNA transcript thereof under physiological conditions. Such hybridization is ordinarily the result of base-specific hydrogen bonding between complementary strands, preferably to form Watson-Crick or Hoogsteen base pairs, although other modes of hydrogen bonding, as well as base stacking can lead to hybridization. As a practical matter, such hybridization can be inferred from the observation of specific gene expression inhibition, which may be at the level of transcription or translation (or both).
Particularly preferred antisense ohgonucleotides utilized in this aspect of the invention include chimeric ohgonucleotides and hybrid ohgonucleotides.
For purposes of the invention, a "chimeric ohgonucleotide" refers to an ohgonucleotide having more than one type of intemucleoside linkage. One preferred embodiment of such a chimeric ohgonucleotide is a chimeric ohgonucleotide comprising a phosphorothioate, phosphodiester or phosphorodithioate region, preferably comprising from about 2 to about 12 nucleotides, and an alkylphosphonate or alkylphosphonothioate region (see e.g., Pederson et al. U.S. Patent Nos. 5,635,377 and 5,366,878). Preferably, such chimeric oligonucleotides contain at least three consecutive intemucleoside linkages selected from phosphodiester and phosphorothioate linkages, or combinations thereof.
For purposes of the invention, a "hybrid oligonucleotide" refers to an ohgonucleotide having more than one type of nucleoside. One preferred embodiment of such a hybrid oligonucleotide comprises a ribonucleotide or 2'-O-substituted ribonucleotide region, preferably comprising from about 2 to about 12 2'-O-substituted nucleotides, and a deoxyribonucleotide region. Preferably, such a hybrid oligonucleotide will contain at least three consecutive deoxyribonucleosides and will also contain ribonucleosides, 2'-O- substituted ribonucleosides, or combinations thereof (see e.g., Metelev and Agrawal, U.S. Patent No. 5,652,355).
The exact nucleotide sequence and chemical structure of an antisense ohgonucleotide utilized in the invention can be varied, so long as the ohgonucleotide retains its ability to inhibit expression of a histone deacetylase. This is readily determined by testing whether the particular antisense oligonucleotide is active by quantitating the amount of mRNA encoding a histone deacetylase, quantitating the amount of histone deacetylase protein, quantitating the histone deacetylase enzymatic activity, or quantitating the abihty of histone deacetylase to inhibit cell growth in a an in vitro or in vivo cell growth assay, all of which are described in detail in this specification.
Antisense oligonucleotides utilized in the invention may conveniently be synthesized on a suitable solid support using well-known chemical approaches, including H-phosphonate chemistry, phosphoramidite chemistry, or a combination of H-phosphonate chemistry and phosphoramidite chemistry (i.e., H-phosphonate chemistry for some cycles and phosphoramidite chemistry for other cycles). Suitable sohd supports include any of the standard solid supports used for solid phase ohgonucleotide synthesis, such as controlled- pore glass (CPG) (see, e.g., Pon, R. T., Methods in Molec. Biol. 20: 465-496, 1993).
Antisense oligonucleotides according to the invention are useful for a variety of purposes. For example, they can be used as "probes" of the physiological function of histone deacetylase by being used to inhibit the activity of histone deacetylase in an experimental cell culture or animal system and to evaluate the effect of inhibiting such histone deacetylase activity. This is accomplished by administering to a cell or an animal an antisense oligonucleotide that inhibits histone deacetylase expression according to the invention and observing any phenotypic effects. In this use, the antisense oligonucleotides according to the invention is preferable to traditional "gene knockout" approaches because it is easier to use,
and can be used to inhibit histone deacetylase activity at selected stages of development or differentiation. Thus, the method according to the invention can serve as a probe to test the role of histone deacetylation in various stages of development.
Preferred antisense ohgonucleotides of the invention inhibit either the transcription of a nucleic acid molecule encoding the histone deacetylase, or the translation of a nucleic acid molecule encoding the histone deacetylase. Histone deacetylase-encoding nucleic acids may be RNA or double stranded DNA regions and include, without limitation, intronic sequences, untranslated 5' and 3' regions, intron-exon boundaries as well as coding sequences from a histone deacetylase family member gene. For human sequences, see e.g., Yang et al., Proc. Natl. Acad. Sci. USA 93(23): 12845-12850, 1996; Furukawa et al, Cytogenet. Cell Genet. 73(1-2): 130-133, 1996; Yang et al., J. Biol. Chem. 272(44): 28001-28007, 1997; Betz et al, Genomics 52(2): 245-246, 1998; Taunton et al., Science 272(5260): 408-411, 1996; and Dangond et al., Biochem. Biophys. Res. Commun. 242(3): 648-652, 1998).
Particularly preferred non- limiting examples of antisense oligonucleotides of the invention are complementary to regions of RNA or double- stranded DNA encoding a histone deacetylase (e.g., HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E). The antisense ohgnouncleotides according to the invention are complementary to regions of RNA or double-stranded DNA that encode HDAC-1, HDAC-2, HDAC-3, HDAC- 4, HDAC-5, HDAC-C, HDAC-D, and/or HDAC-E. The sequence of human HDAC-1 can be found in GenBank Accession No. U50079 (amino acid sequence in SEQ ID NO:24; nucleic acid sequence in SEQ ID NO:25. The sequence of human HDAC-2 can be found in GenBank Accession No. U31814 (amino acid sequence in SEQ ID NO: 26; nucleic acid sequence in SEQ ID NO: 27). The sequence of human HDAC-3 can be found in GenBank Accession No. U75697 (amino acid sequence in SEQ ID NO: 28; nucleic acid sequence in SEQ ID NO: 29). The sequence of human HDAC-4 (formerly human HDAC-A) in GenBank Accession No. AB006626 (amino acid sequence in SEQ ID NO: 30; nucleic acid sequence in SEQ ID NO: 31). The sequence of human HDAC-5 (formerly human HDAC-B) can be found in GenBank Accession No. ABOl 1172 (amino acid sequence in SEQ ID NO: 32; nucleic acid sequence in SEQ ID NO: 33). The sequence of human HDAC-C can be found in GenBank Accession No. AC004994 (amino acid sequence in SEQ ID NO: 34; nucleic acid
sequence in SEQ ID NO: 35). The sequence of human HDAC-D can be found in GenBank Accession No. AC004466 (nucleic acid sequence in SEQ ID NO: 36).
The sequences encoding histone deacetylases from many non-human animal species are also known (see, for example, GenBank Accession Numbers AF006603, AF006602,and AF074882 for murine histone deacetylases). Accordingly, the antisense oligonucleotides of the invention may also be complementary to regions of RNA or double-stranded DNA that encode histone deacetylases from non-human animals. Particularly, preferred ohgonucleotides have nucleotide sequences of from about 13 to about 35 nucleotides which include the nucleotide sequences shown below as SEQ ID NOs: 1-18. Yet additional particularly preferred ohgonucleotides have nucleotide sequences of from about 15 to about 26 nucleotides of the nucleotide sequences shown below. Most preferably, the ohgonucleotides shown below have phosphorothioate backbones, are 20-26 nucleotides in length, and are modified such that the terminal four nucleotides at the 5' end of the ohgonucleotide and the terminal four nucleotides at the 3' end of the ohgonucleotide each have 2' -O- methyl groups attached to their sugar residues.
Antisense ohgonucleotide specific for human HDAC-1 (MG2608): 5'-GAA ACG TGA GGG ACT CAG CA-3' (SEQ ID NO: 1).
Antisense ohgonucleotide specific for both human HDAC-1 and human HDAC-2 (MG2610) is a 25/25/25/25 mixture of four ohgonucleotides: 5'- CAG CAA ATT ATG GGT CAT GCG GAT TC-3' (SEQ ID NO: 2); 5'- CAG CAA GTT ATG AGT CAT GCG GAT TC-3' (SEQ ID NO: 3); 5'- CAG CAA ATT ATG AGT CAT GCG GAT TC-3' (SEQ ID NO: 4); and 5'- CAG CAA GTT ATG GGT CAT GCG GAT TC-3' (SEQ ID NO: 5). Antisense oligonucleotide specific for human HDAC-2: 5'-TGC TGC TGC TGC TGC TGC CG-3' (MG2628; SEQ ID NO: 6); 5'-CCT CCT GCT GCT GCT GCT GC-3' (MG2633; SEQ ID NO: 7); 5'-GGT TCC TTT GGT ATC TGT TT-3' (MG2635; SEQ ID NO: 8); and 5'-CTC CTT GAC TGT ACG CCA TG-3' (MG2636; SEQ ID NO: 9).
The antisense oligonucleotides according to the invention may optionally be formulated with any of the well known pharmaceutically acceptable carriers or diluents (see
preparation of pharmaceutically acceptable formulations in, e.g.. Remington's Pharmaceutical Sciences, 18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, PA, 1990).
In a second aspect, the invention provides a method for inhibiting a histone deacetylase in a cell comprising contacting the cell with the antisense ohgonucleotide that inhibits the expression of a histone deacetylase. Preferably, cell prohferation is inhibited in the contacted cell. Thus, the antisense oligonucleotides according to the invention are useful in therapeutic approaches to human diseases including benign and malignant neoplasms by inhibiting cell prohferation in cells contacted with the antisense ohgonucleotides. The phrase "inhibiting cell prohferation" is used to denote an ability of a histone deacetylase antisense ohgonucleotide or a histone deacetylase protein inhibitor (or combination thereof) to retard the growth of cells contacted with the ohgonucleotide or protein inhibitor, as compared to cells not contacted. Such an assessment of cell proliferation can be made by counting contacted and non-contacted cells using a Coulter Cell Counter (Coulter, Miami, FL) or a hemacyto meter. Where the cells are in a sohd growth (e.g., a sohd tumor or organ), such an assessment of cell prohferation can be made by measuring the growth with calipers, and comparing the size of the growth of contacted cells with non-contacted cells. Preferably, the term includes a retardation of cell prohferation that is at least 50% of non-contacted cells. More preferably, the term includes a retardation of cell prohferation that is 100% of non- contacted cells (i.e., the contacted cells do not increase in number or size). Most preferably, the term includes a reduction in the number or size of contacted cells, as compared to non- contacted cells. Thus, a histone deacetylase antisense oligonucleotide or a histone deacetylase protein inhibitor that inhibits cell proliferation in a contacted cell may induce the contacted cell to undergo growth retardation, to undergo growth arrest, to undergo programmed cell death (i.e., to apoptose), or to undergo necrotic cell death.
Conversely, the phrase "inducing cell prohferation" is used to denote the requirement of the presence or enzymatic activity of a histone deacetylase for cell proliferation in a normal (i.e., non-neoplastic) cell. Hence, over-expression of a histone deacetylase that induces cell proliferation may or may not lead to increased cell proliferation; however, inhibition of a histone deacetylase that induces cell proliferation will lead to inhibition of cell proliferation.
The phrase "inducing cell differentiation" is used to denote the ability of a histone deacetylase antisense oligonucleotide or histone deacetylase protein inhibitor (or combination thereof) to induce differentiation in a contacted cell as compared to a cell that is not contacted. Thus, a neoplastic cell, when contacted with a histone deacetylase antisense ohgonucleotide or histone deacetylase protein inhibitor (or both) of the invention, may be induced to differentiate, resulting in the production of a daughter cell that is phylogenetically more advanced than the contacted cell.
The cell prohferation inhibiting ability of the antisense ohgonucleotides according to the invention allows the synchronization of a population of a-synchronously growing cells. For example, the antisense oligonucleotides of the invention may be used to arrest a population of non- neoplastic cells grown in vitro in the Gl or G2 phase of the cell cycle. Such synchronization allows, for example, the identification of gene and/or gene products expressed during the Gl or G2 phase of the cell cycle. Such a synchronization of cultured cells may also be useful for testing the efficacy of a new transfection protocol, where transfection efficiency varies and is dependent upon the particular cell cycle phase of the cell to be transfected. Use of the antisense ohgonucleotides of the invention allows the synchronization of a population of cells, thereby aiding detection of enhanced transfection efficiency.
The anti-neoplstic utility of the antisense ohgonucleotides according to the invention is described in detail elsewhere in this specification.
In yet other preferred embodiments, the cell contacted with a histone deacetylase antisense ohgonucleotide is also contacted with a histone deacetylase protein inhibitor.
As used herein, the term "histone deacetylase protein inhibitor" denotes an active moiety capable of interacting with a histone deacetylase at the protein level and reducing the activity of that histone deacetylase. Histone deacetylase protein inhibitors include, without limitation, trichostatin A, trichostatin B, trichostatin C, depudecin, trapoxin, butyrate, suberoylanilide hydroxamic acid (SAHA), FR901228 (Fujisawa Pharmaceuticals), and acetyldinaline (el-Beltagi et al., Cancer Res. 53(13):3008-3014, 1993). A histone deacetylase protein inhibitor is a molecule that reduces the activity of a histone deacetylase to a greater extent than it reduces the activity of any unrelated protein. In a preferred embodiment, such reduction of the activity of a histone deacetylase is at least 5-fold, more preferably at least
10-fold, most preferably at least 50-fold. In another embodiment, the activity of a histone deacetylase is reduced 100-fold. Preferably, a histone deacetylase protein inhibitor interacts with and reduces the activity of fewer than all histone deacetylases. By "all histone deacetylases" is meant all of the members of both of the histone deacetylase families of proteins from a particular species of animal and includes, without limitation, HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E, all of which are considered "related proteins," as used herein. For example, a preferred histone deacetylase protein inhibitor interacts with and inhibits HDAC- 1 and HDAC-2, but does not interact with and inhibit HDAC-3. Most preferably, a histone deacetylase protein inhibitor interacts with and reduces the activity of one histone deacetylase (e.g., HDAC-2), but does not interact with or reduce the activities of the other histone deacetylases (e.g., HDAC-1 and HDAC-3). As discussed below, a preferred histone deacetylase protein inhibitor is one that interacts with and reduces the enzymatic activity of a histone deacetylase that is involved in tumorigenesis. Preferably, the histone deacetylase protein inhibitor is operably associated with the antisense oligonucleotide. As mentioned above, the antisense oligonucleotides according to the invention may optionally be formulated well known pharmaceutically acceptable carriers or diluents. This formulation may further contain one or more one or more additional histone deacetylase antisense oligonucleotide(s), and/or one or more histone deacetylase protein inhibitor(s), or it may contain any other pharmacologically active agent. In a particularly preferred embodiment of the invention, the antisense oligonucleotide is in operable association with a histone deacetylase protein inhibitor. The term "operable association" includes any association between the antisense ohgonucleotide and the histone deacetylase protein inhibitor which allows an antisense oligonucleotide to inhibit histone deacetylase-encoding nucleic acid expression and allows the histone deacetylase protein inhibitor to inhibit histone deacetylase enzymic activity. One or more antisense ohgonucleotide of the invention may be operably associated with one or more histone deacetylase protein inhibitor. Preferably, an antisense oligonucleotide of the invention that targets one particular histone deacetylase (e.g., HDAC-2) is operably associated with a histone deacetylase protein inhibitor which targets the same histone deacetylase. A preferred operable association is a hydrolyzable. Preferably, the hydrolyzable association is a covalent linkage between the antisense oligonucleotide and the histone deacetylase protein inhibitor.
Preferably, such covalent linkage is hydrolyzable by esterases and/or amidases. Examples of such hydrolyzable associations are well known in the art. Phosphate esters are particularly preferred.
In certain preferred embodiments, the covalent linkage may be directly between the antisense oligonucleotide and the histone deacetylase protein inhibitor so as to integrate the histone deacetylase protein inhibitor into the backbone. Alternatively, the covalent linkage may be through an extended structure and may be formed by covalently linking the antisense ohgonucleotide to the histone deacetylase protein inhibitor through coupling of both the antisense oligonucleotide and the histone deacetylase protein inhibitor to a carrier molecule such as a carbohydrate, a peptide or a lipid or a glycohpid. Other preferred operable associations include lipophilic association, such as formation of a hposome containing an antisense ohgonucleotide and the histone deacetylase protein inhibitor covalently linked to a lipophilic molecule and thus associated with the liposome. Such hpophilic molecules include without hmitation phosphotidylcholine, cholesterol, phosphatidylethanolamine, and synthetic neoglycohpids, such as syalyllacNAc-HDPE. In certain preferred embodiments, the operable association may not be a physical association, but simply a simultaneous existence in the body, for example, when the antisense ohgonucleotide is associated with one liposome and the protein effector is associated with another hposome.
In a third aspect, the invention provides a method for inhibiting neoplastic cell proliferation in an animal comprising administering to an animal having at least one neoplastic cell present in its body a therapeutically effective amount of the antisense oligonucleotide of the first aspect of the invention with a pharmaceutically acceptable carrier for a therapeutically effective period of time. Preferably, the animal is a mammal, particularly a domesticated mammal. Most preferably, the animal is a human. The term "neoplastic cell" is used to denote a cell that shows aberrant cell growth.
Preferably, the aberrant cell growth of a neoplastic cell is increased cell growth. A neoplastic cell may be a hyperplastic cell, a cell that shows a lack of contact inhibition of growth in vitro, a benign tumor cell that is incapable of metastasis in vivo, or a cancer cell that is capable of metastases in vivo and that may recur after attempted removal. The term "tumorigenesis" is used to denote the induction of cell proliferation that leads to the development of a neoplastic growth.
The terms "therapeutically effective amount" and "therapeutically effective period of time" are used to denote known treatments at dosages and for periods of time effective to reduce neoplastic cell growth. Preferably, such administration should be parenteral, oral, sublingual, transdermal, topical, intranasal, or intrarectal. When administered systemically the therapeutic composition is preferably administered at a sufficient dosage to attain a blood level of antisense oligonucleotide from about 0.1 μM to about 10 μM. For locahzed administration, much lower concentrations than this may be effective, and much higher concentrations may be tolerated. One of skill in the art will appreciate that such therapeutic effect resulting in a lower effective concentration of the histone deacetylase inhibitor may vary considerably depending on the tissue, organ, or the particular animal or patient to be treated according to the invention.
In a preferred embodiment, the therapeutic composition of the invention is administered systemically at a sufficient dosage to attain a blood level of antisense ohgonucleotide from about 0.01 μM to about 20 μM. In a particularly preferred embodiment, the therapeutic composition is administered at a sufficient dosage to attain a blood level of antisense ohgonucleotide from about 0.05 μM to about 15 μM. In a more preferred embodiment, the blood level of antisense ohgonucleotide is from about 0.1 μM to about 10 μM.
For locahzed administration, much lower concentrations than this may be therapeutically effective. Preferably, a total dosage of antisense oligonucleotide will range from about 0.1 mg to about 200 mg ohgonucleotide per kg body weight per day. In a more preferred embodiment, a total dosage of antisense ohgonucleotide will range from about 1 mg to about 20 mg oligonucleotide per kg body weight per day. In a most preferred embodiment, a total dosage of antisense oligonucleotide will range from about 2 mg to about 10 mg ohgonucleotide per kg body weight per day. In a particularly preferred embodiment, the therapeutically effective amount of a histone deacetylase antisense oligonucleotide is about 0.5 mg ohgonucleotide per kg body weight per day.
In certain preferred embodiments of the third aspect of the invention, the method further comprises administering to the animal a therapeutically effective amount of a histone deacetylase protein inhibitor with a pharmaceutically acceptable carrier for a therapeutically effective period of time. Preferably, the histone deacetylase protein inhibitor is operably
associated with the antisense oligonucleotide. Methods for the operable association of a histone deacetylase protein inhibitor with a histone deacetylase antisense oligonucleotide are described above.
The histone deacetylase protein inhibitor-containing therapeutic composition of the invention is administered systemically at a sufficient dosage to attain a blood level histone deacetylase protein inhibitor from about O.OlμM to about lOμM. In a particularly preferred embodiment, the therapeutic composition is administered at a sufficient dosage to attain a blood level of histone deacetylase protein inhibitor from about 0.05μM to about lOμM. In a more preferred embodiment, the blood level of histone deacetylase protein inhibitor is from about 0. lμM to about 7μM. For localized administration, much lower concentrations than this may be effective. Preferably, a total dosage of histone deacetylase protein inhibitor will range from about 0.01 mg to about 5 mg protein effector per kg body weight per day. In a more preferred embodiment, a total dosage of histone deacetylase protein inhibitor will range from about 0.1 mg to about 4 mg protein effector per kg body weight per day. In a most preferred embodiment, a total dosage of histone deacetylase protein inhibitor will range from about 0.1 mg to about 1 mg protein effector per kg body weight per day. In a particularly preferred embodiment, the therapeutically effective synergistic amount of histone deacetylase protein inhibitor (when administered with an antisense ohgonucleotide) is 0.1 mg per kg body weight per day. This aspect of the invention results in an improved inhibitory effect, thereby reducing the therapeutically effective concentrations of either or both of the nucleic acid level inhibitor (i.e., antisense oligonucleotide) and the protein level inhibitor (i.e., histone deacetylase protein inhibitor) required to obtain a given inhibitory effect as compared to those necessary when either is used individually. Furthermore, one of skill will appreciate that the therapeutically effective synergistic amount of either the antisense ohgonucleotide or the histone deacetylase inhibitor may be lowered or increased by fine tuning and altering the amount of the other component. The invention therefore provides a method to tailor the administration/treatment to the particular exigencies specific to a given animal species or particular patient. Therapeutically effective ranges may be easily determined for example empirically by starting at relatively low amounts and by step-wise increments with concurrent evaluation of inhibition.
In a fourth aspect, the invention provides a method for investigating the role of a particular histone deacetylase in cellular prohferation, including the proliferation of neoplastic cells. In this method, the cell type of interest is contacted with an amount of an antisense ohgonucleotide that inhibits the expression of a histone deacetylase, as described for the first aspect according to the invention, resulting in inhibition of expression of the histone deacetylase in the cell. If the contacted cell with inhibited expression of the histone deacetylase also shows an inhibition in cell proliferation, then the histone deacetylase is involved in the induction of cell prohferation. In this scenario, if the contacted cell is a neoplastic cell, and the contacted neoplastic cell shows an inhibition of cell proliferation, then the histone deacetylase whose expression was inhibited is a histone deacetylase that is involved in tumorigenesis. Preferably, the histone deacetylase is HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E.
Thus, by identifying a particular histone deacetylase that is involved in the induction of cell proliferation, only that particular histone deacetylase need be targeted with an antisense ohgonucleotide to inhibit cell proliferation or induce differentiation. Consequently, a lower therapeutically effective dose of antisense ohgonucleotide may be able to effectively inhibit cell prohferation. Moreover, undesirable side effects of inhibiting all histone deacetylases may be avoided by specifically inhibiting the one (or more) histone deacetylase(s) involved in inducing cell prohferation. Once such a histone deacetylase involved in inducing cell prohferation is identified using the antisense oligonucleotides of the first aspect of the invention, then histone deacetylase protein inhibitors may be generated that specifically inhibit the histone deacetylase involved in inducing cell proliferation, while not inhibiting other histone deacetylases not involved in inducing cell proliferation. Accordingly, in a fifth aspect, the invention provides a method for identifying a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in the induction of cell prohferation. This method comprises contacting a histone deacetylase identified as being involved in inducing cell proliferation with a candidate compound and measuring the enzymatic activity of the contacted histone deacetylase. A reduction in the enzymatic activity of the contacted histone deacetylase identifies the candidate compound as a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell prohferation.
Measurement of the enzymatic activity of a histone deacetylase can be achieved using known methodologies. For example, Yoshida et al. (J. Biol. Chem. 265: 17174-17179, 1990) describe the assessment of histone deacetylase enzymatic activity by the detection of acetylated histones in trichostatin A treated cells. Taunton et al. (Science 272: 408-411, 1996) similarly describes methods to measure histone deacetylase enzymatic activity using endogenous and recombinant HDAC-1. Both Yoshida et al. (J. Biol. Chem. 265: 17174- 17179, 1990) and Taunton et al. (Science 272: 408-411, 1996) are hereby incorporated by reference.
Preferably, the histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell proliferation is a histone deacetylase protein inhibitor that interacts with and reduces the enzymatic activity of fewer than all histone deacetylases.
In a sixth aspect, the invention provides a method for identifying a histone deacetylase that is involved in induction of cell differentiation comprising contacting a cell with an antisense oligonucleotide that inhibits the expression of a histone deacetylase, wherein induction of differentiation in the contacted cell identifies the histone deacetylase as a histone deacetylase that is involved in induction of cell differentiation. Preferably, the cell is a neoplastic cell. In preferred embodiments, the histone deacetylase is HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, or HDAC-E.
In a seventh aspect, the invention provides a method for identifying a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell differentiation comprising contacting a histone deacetylase identified by the method of the sixth aspect of the invention with a candidate compound and measuring the enzymatic activity of the contacted histone deacetylase, wherein a reduction in the enzymatic activity of the contacted histone deacetylase identifies the candidate compound as a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in induction of cell differentiation. In certain preferred embodiments, the histone deacetylase protein inhibitor interacts with and reduces the enzymatic activity of fewer than all histone deacetylases.
In an eighth aspect, the invention provides a histone deacetylase protein inhibitor identified by the method of the fifth or the seventh aspects of the invention. Preferably, the histone deacetylase protein inhibitor is substantially pure.
Substantially purified proteins can be achieve by any standard method including, without limitation, expression of recombinant protein, affinity chromatography, antibody- based affinity purification, and high performance hquid chromatography (HPLC; see, e.g., Fisher (1980) Laboratory Techniques in Biochemistry and Molecular Biology, Work and Burdon (eds.), Elsevier). Preferably, a substantially purified protein is at least 80%, by weight, pure in that it is free from other proteins or naturally-occurring organic molecules. More preferably, a substantially purified protein is at least 90% pure, by weight. Most preferably, a substantially purified protein is at least 95% pure, by weight.
In a ninth aspect, the invention provides a method for inhibiting cell proliferation in a cell comprising contacting a cell with at least two of the reagents selected from the group consisting of an antisense ohgonucleotide that inhibits a histone deacetylase, a histone deacetylase protein inhibitor, an antisense ohgonucleotide that inhibits a DNA methyltransferase, and a DNA methyltransferase protein inhibitor. In one embodiment, the inhibition of cell growth of the contacted cell is greater than the inhibition of cell growth of a cell contacted with only one of the reagents. In certain preferred embodiments, each of the reagents selected from the group is substantially pure. In preferred embodiments, the cell is a neoplastic cell. In yet additional preferred embodiments, the reagents selected from the group are operably associated.
Antisense oligonucleotides that inhibit DNA methyltransferase are described in Szyf and von Hofe, U.S. Patent No. 5,578,716, the entire contents of which are incorporated by reference. DNA methyltransferase protein inhibitors include, without hmitation, 5-aza-2'- deoxycytidine (5-aza-dC), 5-fluoro-2'-deoxycytidine, 5-aza-cytidine (5-aza-C), or 5,6- dihydro-5-aza-cytidine.
The following examples are intended to further illustrate certain preferred embodiments of the invention and are not hmiting in nature. Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are considered to be within the scope of this invention, and are covered by the appended claims.
Example 1 Screening of Antisense Oligonucleotides To identify which antisense ohgonucleotides were most effective at inhibiting a specific histone deacetylase, a number of oligonucleotides were generated based on the sequences provided in GenBank Accession Number U50079 for HDAC-1 and GenBank Accession Number U31814 for HDAC-2. Some of the oligonucleotides screened were described in Table 2 and Table 3 of Besterman et al., U.S. patent apphcation serial no. 60/104,804, filed October 19, 1998, the entire disclosure of which is hereby incorporated by reference. In addition, ohgonucleotides were generated which were complementary to both
HDAC-1 and HDAC-2.
To screen these oligonucleotides for an ability to inhibit the targeted histone deacetylase, a Northern blotting analysis was first performed. To do this, T24 human bladder carcinoma cells (commercially available from the American Type Culture Collection (ATCC), Manassas, VA) were grown under suggested conditions. Before addition of ohgonucleotides, cells were washed with PBS (phosphate buffered saline). Next, hpofectin transfection reagent (Gibco-BRL Mississauga, Ontario), at a concentration of 6.25 μg/ml, was added to serum free OPTIMEM medium (GIBCO/BRL), which was then added to the cells. Ohgonucleotides to be screened were then added to different wells of cells (i.e., one oligonucleotide per well of cells). The same concentration of oligonucleotide (e.g., 50 nM) was used per well of cells. The cells were allowed to incubate with lipofectin and ohgonucleotide for 4 hours at 37 C in a cell culture incubator. The cells were then washed with PBS and returned to full serum-containing medium. Twenty- four hours later, the cells were harvested for determination of HD AC mRNA levels by Northern blotting analysis. For determination of mRNA levels by Northern blot, total RNA was prepared from cells by the guanidinium isothiocyanate standard procedure (see, e.g., Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, 1994), with the exception of an additional precipitation step in 2 M LiCl overnight at 4°C to purify RNA from cellular DNA contamination. Northern blotting analysis was performed according to standard protocols. Probes for HDAC-1 and HDAC-2 were full length cDNA clones generated by PCR amplification from the known sequences for each (e.g., GenBank
Accession Nos. U50079 and U31814, respectively). These probes were radio labelled with
32 P-ATP. Northern blots were scanned and quantified using Alpha Imager (Alpha Innovotech).
The oligonucleotides which showed an ability to reduce the mRNA expression of a targeted histone deacetylase (i.e., were able to inhibit transcription of the histone deacetylase mRNA) were next screened for an abihty to inhibit expression of the targeted histone deacetylase protein. To do this, T24 cells were transfected with ohgonucleotide using lipofectin as described above. Twenty-four hours later, the cells were lysed according to standard procedures. The whole cell extracts (50 μg) were resolved on 7-15% gradient SDS PAGE, transferred to PVDF membrane (Amersham, Arlington Heights, IL), and subjected to Western blotting analysis with rabbit polyclonal HDACl- and HDAC-2 specific antibodies (1:500, Santa Cmz Biotech., Santa Cruz, CA) were used. Detection was accomplished with a secondary anti- rabbit IgG-HR peroxidase antibody and an enhanced chemiluminescence detection kit (Amersham) accordingly to manufacturer's instructions. Based on our results, the following antisense ohgonucleotides were identified as being most effective at inhibiting the expression of targeted histone deacetylase as determined by both mRNA and protein expression blotting analysis. These oliognucleotides are as follows: For inhibition of HDAC-1, Ohgonucleotide No. MG2608 having the sequence: 5'-GAA ACG TGA GGG ACT CAG CA-3' (SEQ ID NO: 10). For inhibition of both HDAC- 1 and HDAC-2, Oligonucleotide No. MG2610 is a
25/25/25/25 mixture of four oligonucleotides having the sequences:
5'- CAG CAA ATT ATG GGT CAT GCG GAUUC-3' (SEQ ID NO: 11);
5'- CAG CAAGTT ATG AGT CAT GCG GAUUC-3' (SEQ ID NO: 12);
5'- CAG CAAATT ATG AGT CAT GCG GAUUC-3' (SEQ ID NO: 13); 5'- CAG CAA GTT ATG GGT CAT GCG GAUUC-3' (SEQ ID NO: 14).
For inhibition of HDAC-2, Table I shows the antisense ohgonucleotides found to be most effective:
Table I
(***) target reference numbering is in accordance with HDAC-2, GenBank Accession Number
U31814.
To evaluate the specificity of the second generation histone deacetylase antisense ohgonucleotides, mismatch control ohgonucleotides of HDAC-1 (MG2608) and HDAC-1 / 2 (MG2610) were generated. These mismatch control oligonucleotides were generated by substituting bases, primarily in the four 5' and 3' nucleotides, where the highest affinity with the targeted histone deacetylase-encoding nucleic acid occurs. HDAC- 1 MISMATCH CONTROL (MG2609), has the sequence: 5'-CAA UCG TCA GAG ACT CCG AA-3' (SEQ ID NO: 19).
HDAC-1 / 2 MISMATCH CONTROL (MG2637), has a 225/25/25/25 mixture of four ohgonucleotides having the sequences:
5'-AAG GAAGTC ATG AAT GAT GCC CAUUG-3' (SEQID NO: 20); 5'-AAG GAAATC ATG GAT GAT GCC CAUUG-3' (SEQID NO: 21);
5'-AAG GAAGTC ATG GAT GAT GCC CAUUG-3' (SEQID NO: 22);
5'-AAG GAAATC ATG AAT GAT GCC CAUUG-3' (SEQID NO: 23).
These ohgonucleotides (i.e., having SEQ ID NOs: 10-23) were second generation oligonucleotides (i.e., 4x4 hybrids). That is, oligonucleotides having SEQ ID NOs: 10-23 were chemically modified as follows: A equals 2'-deoxyriboadenosine; C equals 2'- deoxyribocytidine; G equals 2'-deoxyriboguanosine; T equals 2'-deoxyribothymidine; A equals riboadenosine; U equals uridine; C equals ribocytidine; and G equals riboguanosine.
The underlined bases were 2'-methoxyribose substituted nucleotides. Non-underlined bases indicate deoxyribose nucleosides. The backbone of each oligonucleotide consisted of a phosphorothioate linkage between adjoining nucleotides.
A number of oligonucleotides are next generated which are complementary to HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, and HDAC-E. These ohgonucleotides are based on the known nucleic acid sequences of these histone deacetylases (see, e.g., GenBank Accession No. U75697 for HDAC-3). Antisense oligonucleotides specific for one of these histone deacetylases are screened for efficacy at inhibiting expression of mRNA and protein as described above for HDAC-1, HDAC-1 / 2, and HDAC-2. In addition, antisense ohgonucleotides that inhibit more than one histone deacetylase (e.g., HDAC-1 / 3 / C- specific) are also generated by mixing antisense ohgonucleotides specific for each histone deacetylase and screened for efficacy.
Example 2 Inhibition of Histone Deacetylase mRNA Expression With Antisense
Oligonucleotides To determine the specificity and dose requirements of the antisense ohgonucleotides specific for histone deacetylase-encoding nucleic acid, the dose dependent inhibition of these ohgonucleotides on histone deacetylase mRNA expression was examined.
To do this, T24 ceUs were transfected using lipofectin (as described in Example 1) using 10, 25, 50, or 100 nM oligonucleotide. The ceUs were harvested twenty-four hours foUowing transfection, RNA prepared, and Northern blotting analysis performed as described in Example 1 using radio labelled HDAC-1 and HDAC-2 cDNA as probe.
Fig. 1 shows the dose dependent inhibition of HDAC-1 mRNA expression by both HDAC-1 and HDAC-1 / 2 antisense ohgonucleotides at 50-100 nM. Conversely, HDAC-2 mRNA expression was inhibited by only the HDAC-1 / 2 antisense ohgonucleotide (MG2610) at 50-100 nM, while the HDAC-1 antisense oligonucleotide (MG2608) had no effect. The oligonucleotides used in the experiment, the results of which are shown in Fig. 1, were first generation oligonucleotides (i.e., were not chemically modified). The oligonucleotides used to obtain the results shown in Fig. 1 had sequences of SEQ ID NOs: 1- 5.
Fig. 2 shows the dose-dependent inhibition of HDAC-2 mRNA by HDAC-2 antisense oligonucleotide. AU four HDAC-2 antisense oligonucleotide (MG2628, MG2633, MG2635, and MG2636) were able to reduce the level of HDAC-2 mRNA expression at 50-100 nM.
MG2628 appeared particularly efficacious at reducing HDAC-2 mP T expression in this experiment.
These data demonstrated that by targeting histone deacetylase at the nucleic acid level with antisense oligonucleotide, a reduction in mRNA expression could be achieved 24 hours following exposure to the ohgonucleotide.
Example 3
Inhibition of Histone Deacetylase Protein Expression With
Second Generation Antisense Oligonucleotides To determine the ability of histone deacetylase antisense ohgonucleotides to inhibit protein expression, second generation versions of the HDAC-1, HDAC-1 / 2, and HDAC-2 antisense ohgonucleotides were generated. Each of these second generation antisense ohgonucleotides had a backbone consisting of a phosphorothioate linkage between each adjoining nucleotide. Moreover, the four terminal nucleotide residues at both the 5' and 3' ends of the olgonucleotide had sugar residues comprising a 2'-O-methyl group. This modification to the terminal nucleotide residues served to increase binding affinity of the ohgonucleotide to the targeted nucleic acid, and to increase the stability of the ohgonucleotide by inhibiting nuclease susceptibility.
Fig. 3 shows the abUity of second generation HDAC-2 antisense ohgonucleotides to inhibit HDAC-2 protein expression. T24 ceUs were transfected with 0, 25, or 50 nM
MG2628 or MG2636 using lipofectin, as described in Example 1. Twenty-four hours later, the ceUs were transfected a second time with the same amount of the same oligonucleotide. Twenty- four hours after this (i.e., 48 hours after the first transfection), ceUular proteins were prepared, resolved on 7-15% gradient SDS-PAGE, and subjected to Western blotting analysis as described in Example 1 with rabbit polyclonal HDAC2 specific antibody (1:500, Santa Cruz Biotech). Following blotting with the secondary anti- rabbit IgG-HR peroxidase antibody and visualization with the enhanced chemiluminescence detection kit (Amersham), the blot was stripped and re-probed with an antibody specific to actin to verify equal loading of all wells (data not shown). As can be seen in Fig. 3, 50 μM of second generation MG2628 or MG2836 was able to inhibit HDAC-2 protein expression.
Fig. 4 shows the specific ability of the HDAC-1 / 2 and HDAC- , antisense ohgonucleotides to inhibit protein expression of both HDAC-1 and HDAC-2 or HDAC-1, respectively, when compared to the mismatch controls. T24 cells were transfected twice as described above with 50 nM oligonucleotide. Cell lysates were prepared twenty-four hours following the second transfection, resolved on 7-15% gradient SDS-PAGE, and transferred to PNDF membrane. The PVDF membrane blot was first blotted with anti-HDAC-1 antibody. FoUowing detection with horseradish peroxidase-labeUed secondary antibody and enhanced chemiluminescence, the blot was stripped, and re-probed with anti-HDAC-2 antibody. FoUowing detection, the blot was stripped for a second time and re-probed with an actin- specific antibody to verify equal protein loading in the lanes.
As can be seen in Fig. 4, both HDAC-1 and HDAC-1 / 2 mismatch control oligonucleotides failed to inhibit HDAC-1 or HDAC-1 and HDAC-2 protein expression, respectively. Conversely, HDAC-1 antisense ohgonucleotide effectively reduced expression of HDAC-1 protein, and HDAC-1 / 2 antisense oligonucleotide reduced protein expression of both HDAC- 1 and HDAC-2.
Example 4 Identification of A Histone Deacetylase Involved in Induction of Cell Prohferation Antisense ohgonucleotides that inhibit expression of different histone deacetylases, according to the invention, are screened to identify a histone deacetylase that induces cell prohferation in cultured ceUs.
To identify a histone deacetylase that induces normal (i.e., non-neoplastic) cell division, cultured normal human fibroblast ceUs are transfected with an antisense ohgonucleotide that inhibits the expression of a histone deacetylase. While any standard transfection protocol may be employed, including, without limitation, CaPO4 precipitation, electroporation, DEAE-dextran), transfection using the lipofectin transfection reagent (Gibco- BRL) is preferred. Following transfection with lipofectin and a histone deacetylase antisense oligonucleotide, cells are harvested by trypsinization at various time points, and counted using a hemacytometer or a Coulter Cell Counter. Mock transfected control cells (i.e., treated with lipofectin plus a control, non-specific oligonucleotide) are also harvested and counted. Both the antisense oligonucleotide- and mock- transfected cells are also visually inspected
under a microscope for any phenotypic changes (e.g., induction of apoptosis). An antisense oligonucleotide that inhibits the expression of a histone deacetylase that is found to inhibit cell proliferation when transfected into a normal cell identifies a histone deacetylase that is involved in induction of ceU prohferation in normal cells. To identify a histone deacetylase that induces neoplastic cell proliferation, T24 bladder carcinoma ceUs are transfected with histone deacetylase antisense oligonucleotides according to the invention and their growth pattern is observed and compared to that of untransfected control cells. For this purpose, one day before transfection, T24 ceUs (ATCC No. HTB-4) are plated onto 10 cm plates at 4 X 105 ceUs/dish. At the time of transfection, cells are washed with phosphate buffered saline (PBS) and 5 ml of Opti-MEM media
(Gibco-BRL, Mississauga, Ontario) containing 6.25 μg/ml lipofectin transfection reagent is added. The antisense ohgonucleotides to be tested are dUuted to the desired concentration from a 0.1 mM stock solution in the transfection media. After a four-hour incubation at 37°C in a 5% CO2 incubator, the plates are washed with PBS and 10 ml of fresh ceU culture media is added. T24 cells are transfected for a total of three days and split every other day to ensure optimal transfection conditions. At various time points, cells are harvested by trypsinization and pelleted by centrifugation at 1100 rpm and 4°C for five minutes. The cells are resuspended in PBS and counted on a Coulter Particle Counter to determine the total cell number. Mock-transfected T24 ceUs (transfected with lipofectin and a control ohgonucleotide) are similarly grown, harvested, and counted. An antisense ohgonucleotide that inhibits the expression of a histone deacetylase that is found to inhibit ceU proliferation when transfected into a neoplastic cell identifies a histone deacetylase that is involved in induction of cell proliferation in neoplastic ceUs.
By screening a number of different histone deacetylase antisense oligonucleotides in normal and neoplastic cells, a histone deacetylase that is involved in induction of cell proliferation may be readily identified. Most preferably, a histone deacetylase antisense oligonucleotide of the invention is one that inhibits cell proliferation of neoplastic cells, but does not inhibit cell proliferation in normal cells.
Example 5 A Histone Deacetylase Protein Inhibitor that Interacts With and Reduces the Enzymatic Activity of A Histone Deacetylase Involved in the Induction of Cell Proliferation A histone deacetylase that is identified as being involved in the induction of cell proliferation (identified, for example, in the methods of Example 4), is used as a target for candidate compounds designed to interact with and inhibit its enzymatic activity. As a positive control, FR901228 (available from Fujisawa Pharmaceuticals), is used.
Candidate compounds can be derived from any source and may be naturally- occurring or synthetic, or may have naturaUy-occurring and synthetic components. Candidate compounds may also be designed to chemically resemble any of the known histone deacetylase protein inhibitors, including, without hmitation, trichostatin A, trichostatin C, trapoxin, depudecin, suberoylanilide hydro xamic acid (SAHA), FR901228, and butyrate.
Once candidate compounds are identified, a pool of such compounds may be added to a histone deacetylase. Such a histone deacetylase is preferably one that is identified using the antisense ohgonucleotides of the invention as a histone deacetylase involved in induction of ceU prohferation. The histone deacetylase may be purified, for example, by using antibodies specific to that particular histone deacetylase (e.g., anti-HDAC-1 antibody commercially available from Santa Cruz Biotech.) or by recombinant production of the histone deacetylase in prokaryotic or eukaryotic cells. The histone deacetylase may also be present in a ceU which normally expresses the histone deacetylase.
Pools of candidate compounds are added to the histone deacetylase, and the enzymatic activity of the histone deacetylase is measured. A pool of candidate compounds showing such a histone deacetylase inhibiting activity is sub-divided, and the subdivisions tested until one candidate compound is isolated having a histone deacetylase inhibiting activity. It will be understood that once a pool of candidate compounds is identified as having an ability to inhibit histone deacetylase enzymatic activity, the pool may be screened via various methods to ascertain the presence within the pool or one or more histone deacetylase protein inhibitor compounds. For example, if the pool is initially screened in a cell having a histone deacetylase, the pool may be subsequently screened on purified histone deacetylase.
Preferably, the candidate compound(s) found to be a histone & acetylase protein inhibitor inhibits the activity of fewer than aU histone deacetylases. More preferably, such a candidate compound inhibits only those histone deacetylases that are involved in the induction of cell proliferation. Even more preferably, the candidate compound that is identified as a histone deacetylase protein inhibitor is one that inhibits only one histone deacetylase, where that one histone deacetylase is involved in the induction of cell prohferation. Most preferably, the candidate compound that is identified as a histone deacetylase protein inhibitor is one that inhibits only one histone deacetylase, where that one histone deacetylase is involved in the induction of cell prohferation in neoplastic ceUs, but is not involved in the induction of cell prohferation in normal cells.
In another method to identify a candidate compound that is a histone deacetylase protein inhibitor, purified histone deacetylase is allowed to adhere to the bottom of wells in a 96-weU microtiter plate. Candidate compounds (or pools thereof) are then added to the plate, where each candidate compound has been modified with the covalent attachment of a detectable marker (e.g., a biotin label). Binding of the candidate compound to the plate- bound histone deacetylase is detected via addition of a secondary reagent that binds to the detectable marker (e.g., a streptavidin- labelled fluorophore), and subsequent analysis of the plate on a micro-titer plate reader. Candidate compounds thus identified which interact with purified histone deacetylase are then screened for an abUity to inhibit the enzymatic activity of the histone deacetylase.
Example 6 Anti-Neoplastic Effect of Histone Deacetylase Antisense Oligonucleotide on Tumor Cells in Vivo The purpose of this example is to illustrate the abihty of the histone deacetylase antisense ohgonucleotide of the invention to treat diseases responsive to histone deacetylase inhibition in animals, particularly mammals. This example further provides evidence of the ability of the methods and compositions of the invention to inhibit tumor growth in domesticated mammal. Eight to ten week old female BALB/c nude mice (Taconic Labs, Great Barrington, NY) are injected subcutaneously in the flank area with 2 x 106 preconditioned A549 human lung carcinoma cells. Preconditioning of these cells is done by
a minimum of three consecutive tumor transplantations in the same strain of nude mice. Subsequently, tumor fragments of approximately 30 mgs are excised and implanted subcutaneously in mice, in the left flank area under Forene anesthesia (Abbott Labs., Geneva, Switzerland). When the tumors reaches a mean volume of 100 mm3, the mice are treated intravenously, by daily bolous infusion into the taU vein, with ohgonucleotide saline preparations containing 0.1-6 mg/kg of antisense oligonucleotide (Sigma, St. Louis, MO). The optimal final concentration of the oligonucleotide is established by dose response experiments according to standard protocols. Tumor volume is calculated according to standard methods every second day post infusion (e.g., Meyer et al., Int. J. Cancer 43:851- 856 (1989)). Treatment with the ohgonucleotides according to the invention causes a significant reduction in tumor weight and volume relative to controls treated with saline only (i.e., no ohgonucleotide) or controls treated with sahne plus a control, non-specific ohgonucleotide. In addition, the activity of histone deacetylase when measured is expected to be significantly reduced relative to saline treated controls.
Example 7 Synergistic Anti-Neoplastic Effect of Histone Deacetylase Antisense Oligonucleotide and Histone Deacetylase Protein Inhibitor on Tumor Cells in Vivo The purpose of this example is to Ulustrate the abihty of the histone deacetylase antisense ohgonucleotide and the histone deacetylase protein inhibitor of the invention to inhibit tumor growth in a mammal. As described in Example 6, mice bearing implanted A549 tumors (mean volume 100 mm3) are treated daUy with saline preparations containing from about 0.1 mg to about 30 mg per kg body weight of histone deacetylase antisense ohgonucleotide. A second group of mice is treated daily with pharmaceutically acceptable preparations containing from about 0.01 mg to about 5 rag per kg body weight of histone deacetylase protein inhibitor. Some mice receive both the antisense oligonucleotide and the histone deacetylase protein inhibitor. Of these mice, one group may receive the antisense oligonucleotide and the histone deacetylase protein inhibitor simultaneously intravenously via the tail vein. Another group may receive the antisense ohgonucleotide via the tail vein, and the histone deacetylase protein inhibitor subcutaneously. Yet another group may receive both the antisense oligonucleotide and the histone deacetylase protein inhibitor
simultaneously via a subcutaneous injection. Control groups of mice ~e similarly estabhshed which receive no treatment (e.g., saline only), a mismatch antisense oligonucleotide only, a control compound that does not inhibit histone deacetylase activity, and mismatch antisense ohgonucleotide with control compound.
Tumor volume is measured with calipers. Treatment with the antisense oligonucleotide plus the histone deacetylase protein inhibitor according to the invention causes a significant reduction in tumor weight and volume relative to controls. Preferably, the antisense oligonucleotide and the histone deacetylase protein inhibitor inhibit the expression and activity of the same histone deacetylase.
Claims
1. An antisense oligonucleotide that inhibits the expression of a histone deacetylase.
2. The antisense oligonucleotide of claim 1, wherein the histone deacetylase is selected from the group consisting of HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, and HDAC-E.
3. The antisense oligonucleotide of claim 1, wherein the ohgonucleotide inhibits more than one histone deacetylase.
4. The antisense ohgonucleotide of claim 3, wherein the oligonucleotide inhibits aU histone deacetylases.
5. The antisense ohgonucleotide of claim 1, wherein the ohgonucleotide inhibits transcription of a nucleic acid molecule encoding the histone deacetylase.
6. The ohgonucleotide of claim 5, wherein the nucleic acid molecule is selected from the group consisting of genomic DNA, cDNA, and RNA.
7. The antisense ohgonucleotide of claim 1, wherein the oligonucleotide inhibits translation of the histone deacetylase.
8. The antisense oligonucleotide of claim 1, wherein the oligonucleotide has at least one internucleotide linkage selected from the group consisting of phosphorothioate, phosphorodithioate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate, and sulfone internucleotide linkages.
9. The antisense ohgonucleotide of claim 1 , wherein the ohgonucleotide is a chimeric oligonucleotide or a hybrid ohgonucleotide.
10. The antisense ohgonucleotide of claim 1, wherein the ohgonucleotide comprises a ribonucleotide or 2'-O-substituted ribonucleotide region and a deoxyribonucleotide region.
11. A method for inhibiting a histone deacetylase in a ceU comprising contacting the cell with the antisense ohgonucleotide of claim 1.
12. The method of claim 11, wherein cell proliferation is inhibited in the contacted ceU.
13. The method of claim 11, wherein the cell is a neoplastic cell.
14. The method of claim 13, wherein neoplastic ceU is in an animal.
15. The method of claim 14, wherein the neoplastic cell is in a neoplastic growth.
16. The method of claim 11 further comprising contacting the ceU with a histone deacetylase protein inhibitor that interacts with and reduces the enzymatic activity of the histone deacetylase.
17. The method of claim 16, wherein the histone deacetylase protein inhibitor is operably associated with the antisense oligonucleotide.
18. A method for inhibiting neoplastic growth in an animal comprising administering to an animal having at least one neoplastic cell present in its body a therapeutically effective amount of the antisense ohgonucleotide of claim 1 with a pharmaceutically acceptable carrier for therapeutically effective period of time.
19. The method of claim 18, wherein the animal is a mammal.
20. The method of claim 19, wherein the mammal is a hur n.
21. The method of claim 18 further comprising administering to the animal a therapeutically effective amount of a histone deacetylase protein inhibitor that interacts with and reduces the enzymatic activity of the histone deacetylase with a pharmaceutically acceptable carrier for a therapeutically effective period of time.
22. The method of claim 21, wherein the histone deacetylase protein inhibitor is operably associated with the antisense oligonucleotide.
23. A method for identifying a histone deacetylase that is involved in the induction of cell prohferation comprising contacting a cell with an antisense oligonucleotide that inhibits the expression of a histone deacetylase, wherein inhibition of cell proliferation in the contacted ceU identifies the histone deacetylase as a histone deacetylase that is involved in the induction of cell proliferation.
24. The method of claim 23, wherein the cell is a neoplastic cell and the induction of ceU proliferation is tumorigenesis.
25. The method of claim 23, wherein the histone deacetylase is selected from the group consisting of HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, and HDAC-E.
26. A method for identifying a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in the induction of cell proliferation comprising contacting a histone deacetylase identified by the method of claim 23 with a candidate compound and measuring the enzymatic activity of the contacted histone deacetylase, wherein a reduction in the enzymatic activity of the contacted histone deacetylase identifies
the candidate compound as a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in the induction of ceU prohferation.
27. The method of claim 26, wherein the histone deacetylase protein inhibitor interacts with and reduces the enzymatic activity of fewer than all histone deacetylases.
28. A method for identifying a histone deacetylase that is involved in the induction of cell differentiation comprising contacting a cell with an antisense oligonucleotide that inhibits the expression of a histone deacetylase, wherein induction of differentiation in the contacted ceU identifies the histone deacetylase as a histone deacetylase that is involved in the induction of ceU differentiation.
29. The method of claim 28, wherein the cell is a neoplastic cell.
30. The method of claim 28, wherein the histone deacetylase is selected from the group consisting of HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-C, HDAC-D, and HDAC-E.
31. A method for identifying a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in the induction of cell differentiation comprising contacting a histone deacetylase identified by the method of claim 28 with a candidate compound and measuring the enzymatic activity of the contacted histone deacetylase, wherein a reduction in the enzymatic activity of the contacted histone deacetylase identifies the candidate compound as a histone deacetylase protein inhibitor that inhibits a histone deacetylase that is involved in the induction of cell differentiation.
32. The method of claim 31, wherein the histone deacetylase protein inhibitor interacts with and reduces the enzymatic activity of fewer than all histone deacetylases.
33. A histone deacetylase protein inhibitor identified by the method of claim 26 or
31.
34. The histone deacetylase protein inhibitor is substantiaUy pure.
35. A method for inhibiting cell proliferation in a cell comprising contacting a cell with at least two of the reagents selected from the group consisting of an antisense ohgonucleotide that inhibits a histone deacetylase, a histone deacetylase protein inhibitor, an antisense ohgonucleotide that inhibits a DNA methyltransferase, and a DNA methyltransferase protein inhibitor.
36. The method of claim 35, wherein the inhibition of cell growth of the contacted ceU is greater than the inhibition of cell growth of a cell contacted with only one of the reagents.
37. The method of claim 35, wherein the each of the reagents selected from the - group is substantially pure.
38. The method of claim 35, wherein the cell is a neoplastic cell.
39. The method of claim 35, wherein the reagents selected from the group are operably associated.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13228799P | 1999-05-03 | 1999-05-03 | |
US132287P | 1999-05-03 | ||
PCT/IB2000/001252 WO2000071703A2 (en) | 1999-05-03 | 2000-05-03 | Inhibition of histone deacetylase |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1173562A2 true EP1173562A2 (en) | 2002-01-23 |
Family
ID=22453318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00954830A Ceased EP1173562A2 (en) | 1999-05-03 | 2000-05-03 | Inhibition of histone deacetylase |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1173562A2 (en) |
JP (1) | JP2003500052A (en) |
KR (1) | KR20020007398A (en) |
AU (1) | AU6718200A (en) |
CA (1) | CA2366408A1 (en) |
WO (1) | WO2000071703A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015051035A1 (en) | 2013-10-01 | 2015-04-09 | The J. David Gladstone Institutes | Compositions, systems and methods for gene expression noise drug screening and uses thereof |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0005199D0 (en) * | 2000-03-04 | 2000-04-26 | Imp College Innovations Ltd | Modulation of histone deacetylase |
CA2408385A1 (en) * | 2000-03-24 | 2001-09-24 | Methylgene, Inc. | Inhibition of specific histone deacetylase isoforms |
WO2002036783A2 (en) * | 2000-10-31 | 2002-05-10 | Bayer Aktiengesellschaft | Regulation of human histone deacetylase |
JP2005507231A (en) * | 2001-01-10 | 2005-03-17 | アメリカ合衆国 | Histone deacetylase inhibitors in the diagnosis and treatment of thyroid neoplasms |
JP2004520421A (en) * | 2001-01-12 | 2004-07-08 | メチルジーン インコーポレイテッド | Method for specifically inhibiting histone deacetylase-4 |
US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US6706686B2 (en) | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
US20040087657A1 (en) | 2001-10-16 | 2004-05-06 | Richon Victoria M. | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
NZ567758A (en) | 2002-03-04 | 2009-07-31 | Merck Hdac Res Llc | Methods of inducing terminal differentiation using suberoylanilide hydrozmic acid (SAHA) |
US7566535B2 (en) | 2002-03-07 | 2009-07-28 | University Of Delaware | Enhanced oligonucleotide-mediated nucleic acid sequence alteration |
FR2837838B1 (en) * | 2002-03-26 | 2005-01-28 | Exonhit Therapeutics Sa | NOVEL MOLECULAR TARGET FOR NEUROTOXICITY |
AU2003244713A1 (en) * | 2002-03-26 | 2003-10-08 | Exonhit Therapeutics S.A. | Histone deacetylase: novel molecular target of neurotoxicity |
US20040072770A1 (en) * | 2002-07-03 | 2004-04-15 | Besterman Jeffrey M. | Methods for specifically inhibiting histone deacetylase-7 and 8 |
EP1400806A1 (en) * | 2002-09-18 | 2004-03-24 | G2M Cancer Drugs AG | The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity |
EP1570061A2 (en) * | 2002-12-05 | 2005-09-07 | Imperial College Innovations Limited | Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide |
ATE462426T1 (en) | 2003-08-26 | 2010-04-15 | Merck Hdac Res Llc | USING SAHA TO TREAT MESOTHELIOMA |
US20070190022A1 (en) | 2003-08-29 | 2007-08-16 | Bacopoulos Nicholas G | Combination methods of treating cancer |
EP1855111A4 (en) | 2005-03-02 | 2008-10-01 | Astellas Pharma Inc | Novel pd marker for histone deacetylase inhibitor |
BRPI0610322B8 (en) | 2005-05-20 | 2021-05-25 | Methylgene Inc | vegf receptor and hgf receptor signaling inhibitors and pharmaceutical composition |
TWI365068B (en) | 2005-05-20 | 2012-06-01 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
ZA200800901B (en) | 2005-07-14 | 2010-05-26 | Takeda San Diego Inc | Histone deacetylase inhibitors |
WO2007145704A2 (en) | 2006-04-24 | 2007-12-21 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
WO2007146730A2 (en) | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
US8030344B2 (en) | 2007-03-13 | 2011-10-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
KR20110075016A (en) | 2008-10-14 | 2011-07-05 | 닝 시 | Compounds and methods of use |
MY181439A (en) | 2011-02-28 | 2020-12-22 | Sunshine Lake Pharma Co Ltd | Substituted quinoline compounds and methods of use |
US8969388B1 (en) | 2012-07-28 | 2015-03-03 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
TWI574962B (en) | 2012-11-14 | 2017-03-21 | 加拓科學公司 | Heteroaromatic compounds as pi3 kinase modulators and methods of use |
ES2674705T3 (en) | 2013-02-21 | 2018-07-03 | Calitor Sciences, Llc | Heteroaromatic compounds as modulators of PI3 kinase |
US9636298B2 (en) | 2014-01-17 | 2017-05-02 | Methylgene Inc. | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs |
CA3001655C (en) | 2015-10-19 | 2023-08-01 | Sunshine Lake Pharma Co., Ltd. | A salt of egfr inhibitor, crystalline form and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031600A1 (en) * | 1995-04-03 | 1996-10-10 | Hybridon, Inc. | Method of modulating gene expression without depleting complement |
US6777217B1 (en) * | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
JP2002528391A (en) * | 1998-10-19 | 2002-09-03 | メチルジェン,インク. | Modification of gene expression by combination therapy |
-
2000
- 2000-05-03 JP JP2000620080A patent/JP2003500052A/en active Pending
- 2000-05-03 WO PCT/IB2000/001252 patent/WO2000071703A2/en active Application Filing
- 2000-05-03 KR KR1020017014048A patent/KR20020007398A/en not_active Application Discontinuation
- 2000-05-03 AU AU67182/00A patent/AU6718200A/en not_active Abandoned
- 2000-05-03 EP EP00954830A patent/EP1173562A2/en not_active Ceased
- 2000-05-03 CA CA002366408A patent/CA2366408A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO0071703A2 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015051035A1 (en) | 2013-10-01 | 2015-04-09 | The J. David Gladstone Institutes | Compositions, systems and methods for gene expression noise drug screening and uses thereof |
EP3470536A1 (en) | 2013-10-01 | 2019-04-17 | The J. David Gladstone Institutes | Compositions, systems and methods for gene expression noise drug screening and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2366408A1 (en) | 2000-11-30 |
KR20020007398A (en) | 2002-01-26 |
WO2000071703A2 (en) | 2000-11-30 |
WO2000071703A3 (en) | 2001-07-19 |
AU6718200A (en) | 2000-12-12 |
JP2003500052A (en) | 2003-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1173562A2 (en) | Inhibition of histone deacetylase | |
US20070105808A1 (en) | Inhibition of histone deacetylase | |
CA2203652C (en) | A method of down-regulating gene expression | |
JP3054745B2 (en) | Antisense oligonucleotide regulation of raf gene expression | |
US20020082415A1 (en) | Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression | |
CA2882443C (en) | Rnai probes targeting cancer-related proteins | |
WO2002008420A2 (en) | A method of down-regulating gene expression | |
JPH09507502A (en) | Antisense oligonucleotide regulation of raf gene expression | |
EP1438404A2 (en) | Inhibition of specific histone deacetylase isoforms | |
CA2246230A1 (en) | Methoxyethoxy oligonucleotides for modulation of protein kinase c expression | |
EP0846170B1 (en) | Modified protein kinase a-specific oligonucleotides and methods of their use | |
US7635769B2 (en) | Oligoribonucleotide derivatives for specific inhibition of gene expression | |
WO1997011171A9 (en) | Modified protein kinase a-specific oligonucleotides and methods of their use | |
US20020137162A1 (en) | Antisense oligonucleotide inhibition of specific histone deacetylase isoforms | |
US6624293B1 (en) | Modified protein kinase A-specific oligonucleotides and methods of their use | |
US5872007A (en) | CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer | |
US20030083292A1 (en) | Inhibitors of DNA methyltransferase isoforms | |
US5922686A (en) | Oligonucleotide modulation of protein kinase C | |
KR100688045B1 (en) | Antisense oligonucleotides for the inhibition of integrin ?v-subunit expression and a pharmaceutical composition comprising the same | |
CA2223109A1 (en) | Use of antisense oligonucleotides to il-6 receptor mrna to inhibit cellular proliferation | |
WO1996031600A1 (en) | Method of modulating gene expression without depleting complement | |
Barker Jr et al. | Plasmodium falciparum: Effect of Chemical Structure on Efficacy and Specificity of Antisense Oligonucleotides against Malariain Vitro | |
WO1998049287A2 (en) | Antisense oligonucleotides specific for thymidylate synthase | |
WO1999027087A1 (en) | Antisense oligonucleotides specific for cdk4 | |
EP1007656B1 (en) | Modified protein kinase a-specific hybrid oligonucleotide in combination with paclitaxol and methods of their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011105 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20030801 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: METHYLGENE INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20100929 |